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Chapter 1 
General Introdnction 

1.1 Historical perspective 
The first description of islets of ectopic gastric mucosa in the esophagus was by 
Schmidt in 1805 (1). One century later, in 1906, Tileston described peptic 
ulcerations in columnar epithelium lining the distal esophagus (2). In 1950 
Norman Barrett gave a detailed description of the columnar lined esophagus. He 
regarded the distal columnar lined esophagus a mediastinal extension of the 
stomach, as a result of a congenitally short esophagus. Barrett based his theory 
on the nature of the mucosa and mucosal secretions of the columnar lining, 
whereas absence of the musculature and peritoneal covering of the normal 
stomach were ignored (1). In that period Lortat-Jacob described the same 
condition, which he named endobrachyesophagus, a term still used in French 
literature (3). Barrett's observation was that of gastric mucosa, extending as a 
continuous sheet into the mediastinum. He observed that the columnar mucosa 
could extend for a varying distance and could reach as far as the aortic arch. 
Allison and Johnstone in 1953 showed that anatomically and functionally the 
segment of digestive tract described by Barrett is part of the esophagus. These 
authors suggested that the so-called Barrett's esophagus might be an acquired 
rather than a congenital condition. This implies that as a consequence of gastro-
esophageal reflux, oesophageal squamous epithelium is converted to columnar 
epithelium through metaplasia (4). In several studies, authors noted "upward 
migration" of the squamo-columnar junction during follow-up of patients with 
gastro-esophageal reflux (5-7). Animal experiments proved that columnar 
epithelium in the esophagus is generated in the presence of gastro-oesophageal 
reflux (8). Through these observations it had become apparent that Barrett's 
esophagus is an acquired rather than a congenital condition. Around 1980 most 
authors appear to favor the view of the acquired origin of Barrett's esophagus 
(9-14). However, congenital islands of ectopic gastric mucosa do occur. They are 
found in up to 10% of individuals undergoing endoscopy (15). These so called 
"inlet patches" occur principally in the cervical esophagus and are mostly 
surrounded by normal squamous epithelium (16). 
Different mechanism have been proposed for the development of columnar 
epithelium in the esophagus. One suggestion is upward extension of gastric 
epithelium, another is generation of columnar epithelium from superficial 
esophageal glands (heterotopic gastric mucosa). The theory proposing metaplastic 
change of squamous epithelium was already suggested by Allison in 1953. This 
theory was clinically supported by evidence of photographed ulcerations of 
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squamous mucosa which, while healing, were replaced by metaplastic colunmar 
epithelium (17). Further evidence in favor of metaplasia was derived from the 
histology, mucin histochemistry and ultrastructural features of Barrett's 
esophagus. These features of multidirectional differentiation of epithelial cells, 
suggested that the columnar epithelium was derived from a mucosal stem cell 
(18-25). More evidence sustaining the theory of metaplasia from a multi potent 
stem cell was obtained from experiments in dogs. In these experiments, segments 
of esophagus from which the mucosa had been excised were re-epithelialized by 
columnar epithelium when reflux was induced. To prove that this re-
epithelialization was not a process of upward migration of gastric mucosa, a strip 
of normal squamous epithelium between the excised area and stomach was left 
intact (26). 
The epithelium which Barrett described in 1957, in the upper region contained 
flat cells in shallow tubular glands with mucus secreting units but little, if any, 
acid, pepsin or secretin secretion. In the lower esophagus a more typical gastric 
mucous membrane was seen (27). Over time, additional types of aberrant 
columnar epithelium with different secreting and non secreting cell types, such as 
mucous, parietal, chief, neuro-endocrine and goblet cells, were observed (12, 
18-20, 22, 24, 28-30). Paull et aI., distinguished three major types of columnar 
epithelium: an atrophic gastric fundic type with parietal and chief cells; a 
junctional type with cardiac mucous glands and a distinctive specialized columnar 
epithelium with villiform surface, mucous glands and goblet cells (13, 31). These 
authors noted that specialized columnar epithelium is the prevalent type of 
epithelium in Barrett's esophagus. This specialized columnar type appeared to be 
present most proximally in the esophagus, the gastric-fundic type being found 
most distally and the junctional type being ioterposed between the specialized 
columnar and gastric fundic type. This so called zonal expansion theory was 
challenged by Thompson et aI., who described a mosaic pattern of different 
columnar cell types in Barrett's esophagus (22). Other authors confirmed the 
predominance of the specialized intestinal type. With respect to the two other 
types of epithelium the need for adequate sampling in the esophagus was pointed 
out. If sampling is performed blindly under manometric guidance, biopsies taken 
from the cardia could be mistakenly taken for Barrett's esophagus, for instance in 
cases of hiatal herniation of the cardia into the mediastinum (12, 32). 
Endoscopically, the exact gastro-oesophageal junction is difficult to locate. For 
instance, up to 2 cm of simple colunmar lining may be present in the distal 
esophagus of healthy individuals. This led to the agreement that Barrett's 
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few studies reported regression of Barrett's epithelium after successful anti-reflux 
surgery (35, 36). In contrast, in several papers long-term treatment with H2 
receptor blockers (cimetidin) and antacids showed decreased esophagitis and 
induced healing of Barrett's ulcers, but not regression of Barrett's esophagus 
(37 -40). Nevertheless, more recent studies on treatment with proton pump 
inhibitors showed partial regression of Barrett's epithelium (41, 42). 
Barrett already associated columnar lined esophagus with adenocarcinoma in his 
first description (I). Esophageal adenocarcinomas evidently associated with 
Barrett's esophagus were reported a few years later (43). This study was followed 
by numerous other reports, many of which also described dysplastic columnar 
epithelium adjacent to the adenocarcinomas (10, 44-52). Based on these 
observations Barrett's esophagus came to be regarded as a premalignant condition. 
It became clear that progression of Barrett's esophagus to adenocarcinoma is a 
gradual process going through different stages of dysplasia. In analogy to stomach, 
three stages of dysplasia (mild, moderate and severe dysplasia) in Barrett's 
esophagus were defmed (53). Since esophageal adenocarcinomas are highly 
malignant, it lVas recommended that Barrett's esophagus patients should be under 
endoscopic surveillance. A consensus was reached that periodically biopsies taken 
from the mucosa should be screened for dysplastic changes or early carcinoma 
(54). In case of early carcinoma, the patient could be cured by surgical 
intervention. 
1.2 Pl'esent definition 
In Barrett's esophagus the normal stratified squamous mucosal lining of the 
esophagus is replaced by metaplastic columnar epithelium. Three types of 
metaplastic epithelium have been described (l3), but careful examinations proved 
that fundic and gastric type of metaplasia are rarely seen in biopsies taken above 
the lower esophageal sphincter (33). Typical Barrett's epithelium shows 
incomplete intestinal metaplasia with goblet and columnar cells and a flat or 
villiform surface (55, 56). 
Until recently, it was agreed that for diagnosing Barrett's esophagus, the columnar 
epithelium should extend at least three centimeters from the gastro-esophageal 
junction into the esophagus. This margin of three cm of columnar epithelium is 
debatable since endoscopic measurements of the length of columnar lining do not 
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columnar epithelium should extend at least three centimeters from the gastro-
esophageal junction into the esophagus. This margin of three cm of columnar 
epithelium is debatable since endoscopic measurements of the length of columnar 
lining do not appear to be reproducible (57). Furthermore, intestinal metaplasia 
with dysplasia or adenocarcinoma may occur at the gastro-esophageal junction or 
in short segments of Barrett's esophagus (58, 59). 
Regarding the three stages of dysplasia (53), there is limited inter- and intra 
observer agreement, particularly when diagnosing dysplasia less than high grade 
(60). This led to simplification of the dysplasia classification, in which "non 
dysplastic" lesions are distinguished from dysplastic and from unclassifiable 
lesions (mostly regenerative changes), which are marked as "indefinite for 
dysplasia" (61). In practice and for patient management indefinite for dysplasia 
and low grade dysplasia are grouped together. 
When dysplasia occurs it may involve a considerable amount of the columnar 
mucosa or it may be limited in extent (62-64). Therefore, a thorough, systematic 
biopsy protocol is proposed to detect small areas of dysplasia and small 
carcinomas. 
At present, the length of columnar epithelium extending in the esophagus may be 
ignored, four quadrant biopsies at intervals of 2 cm or less throughout the length 
of the Barrett's segment and biopsies of any suspect lesion should be taken. Only 
intestinal metaplasia, which is the prevalent type of Barrett's esophagus, is 
regarded as premalignant. Dysplasia, if present, should be classified as 
indefinite/low grade or high grade dysplasia. 
1.3 Epidemiology, cancer risk and clinical ontcome 
Although it is generally accepted that Barrett's esophagus predisposes for 
esophageal adenocarcinoma, the prevalence of Barrett's esophagus and the 
frequency with which adenocarcinoma occurs in Barrett's esophagus are 
unknown. There is a discrepancy between data derived from clinical and that 
from population based autopsy series. For instance, in a population based study at 
the Mayo Clinic in Rochester USA, in the period of 1980-1986, a 21 fold higher 
prevalence of Barrett's esophagus was reported in autopsy series compared with 
the number of endoscopical diagnoses (65). This important discrepancy is mainly 
caused by the fact that many Barrett's esophagus patients have few symptoms or 
are asymptomatic. The prevalence of Barrett's esophagus is relatively low in 
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childhood and increases with age. A plateau is reached at the age of 60. Median 
age of developing Barrett's esophagus is 40 (66). Interestingly, the prevalence of 
Barrett's esophagus is highest in white middle aged males (67). 
It has become clear that the high incidence of adenocarcinoma in Barrett's 
esophagus as published in the early studies is exaggerated (48, 68, 69). In 
endoscopic series of Barrett's esophagus patients the prevalence of esophageal 
adenocarcinoma is between 8 and 15%. Follow up series, however, shows that 
one case per 46 to 441 patient years of follow up will progress to 
adenocarcinoma. Thus the incidence of adenocarcinoma in Barrett's esophagus 
ranges between 0.2 and 2%. Compared to the general population, the risk for 
developing esophageal adenocarcinoma in Barrett's esophagus is between 30 and 
125 fold increased (70-76). For many years, Barrett's esophagus patients only 
underwent major surgery in case of complete malignant transformation 
(carcinoma) had occurred. Decrease of postoperative mortality and morbidity by 
improved esophageal surgery (77-80), and the frequent coexistence of carcinoma 
with severe dysplasia led to a new approach. In this approach it is suggested that 
surgical intervention should be performed on all Barrett's esophagus patients with 
consistent high grade dysplasia (63, 81-83). 
A striking fact is that in Western countries esophageal adenocarcinoma is the 
most rapidly increasing type of gastrointestinal malignancy (84-87). In the USA 
it shows probably the most rapidly rising incidence rate of all cancers (86). The 
increase in esophageal adenocarcinomas is most marked in higher social 
economic classes, in whites opposed to blacks, and is seven fold higher for males 
than for females (84, 86, 87). At present the incidence of esophageal 
adenocarcinoma lies between 0.6 and 0.8 per 100.000 per year (84-87). It is 
assumed that virtually all esophageal adenocarcinomas are associated with 
Barrett's esophagus. Since the vast majority of Barrett's esophagus is 
unrecognized (72), most esophageal adenocarcinoma associated with Barrett's 
esophagus are discovered when the disease has reached an advanced stage and 
patients already have symptoms of dysphagia and weight loss (69, 72, 88, 89). 
The only possible cure for these patients is esophagogastrectomy. Nevertheless, 
curation by surgery is only feasible in case the disease is limited to the 
esophageal wall and metastases are absent. Therefore, curative resection is only 
attempted after extensive preoperative staging of disease to exclude the presence 
of distal metastases (90-95). For patients with extensive disease and lymph node 
or organ metastases, palliative therapy is a more suitable option (96-104). In 
practice, local or distant lymph node metastases are seen in at least half of the 
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resected specimens. The cumulative five year recurrence rate for metastases in 
patients after esophagogastric resection is approximately 65% (105-107). Overall 
post operative long-term survival of patients with esophageal adenocarcinoma 
ranges between 15 and 60%. However, survival is strongly correlated with the 
stage of the disease. Five years survival of advanced stages, i.e., carcinomas with 
deep infiltration of the esophageal wall and lymph node metastasis, is as low as 
0%, whereas survival rises to 100% in cases where patients are operated with 
disease limited to the mucosa (79, 108-111). 
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Chapter 2 
Prognostic Factors in Barett's Esophagus and 
Esophageal Adenocarcinoma. 

2.1 Biological markers 
Biological markers in neoplastic disease are often factors involved in the 
regulation of normal and abnormal differentiation and proliferation of cells. In 
oncology, these markers can be used as parameters to diagnose at tissue level or 
to clinically monitor disease. In Barrett's esophagus the development of an 
adenocarcinoma involves many factors interacting in a complex manner rather 
than a simple transforming hit. Some factors can be detected early and others late 
during neoplastic progression, but an exact order of involvement of the various 
factors in malignant transformation in Barrett's esophagus has not been 
determined. Generally, markers which may be used in Barrett's esophagus 
include: Secretory factors, cell cycle regulating factors, onco- and tumor 
suppressor genes, cell surface proteins, genetic aberrations and ploidy status. 
Most of these have been extensively correlated with histopathological changes in 
Barrett's esophagus, but few have been evaluated in prospective follow-up series, 
in order to determine their prognostic significance. 
Many markers evaluated in Barrett's esophagus have also been studied in 
esophageal adenocarcinomas. Some have even been correlated with clinico 
pathological parameters, such as tumor stage, grade and patient survival. 
2.2 Secretory factors 
Barrett's esophagus consists of a mixed population of secretory and non secretory 
cells, such as columnar, goblet, Paneth and endocrine cells. Most of the mucin 
secreted is of the neutral type, but sulphomucins and sialomucins can be found as 
well. The presence of sulphomucins, although previously reported to be a risk 
factor for adenocarcinoma (21,23, 112) appears to be common in the intestinal 
type of Barrett's metaplasia and cannot be considered a marker for malignant 
transformation (55, 113). Decreased secretion of O-acetylated sialomucins was 
found in all dysplastic but also in a number of non·dysplastic cases of Barrett's 
esophagus with incomplete intestinal type of metaplasia (114). Likewise, sucrase-
isomaltase expression was found in incomplete intestinal type of metaplasia and in 
esophageal adenocarcinomas (115). Glutathione and Glutathione-S transferase 
enzyme activity is low in Barrett's esophagus. These enzymes protect tissues 
from genetic damage, for instance, caused by oxygen radicals. Decreased levels 
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have been correlated with an increased risk of malignant transformation (116). 
Increasing levels of Ornithine decarboxylase (ODC) have been frequently found 
in metaplastic, dysplastic and neoplastic Barrett's esophagus and this may be 
regarded as a biochemical marker for malignant progression (117, 118). ODC 
catalyzes polyamine synthesis and is an important enzyme for cell proliferation 
and differentiation. Despite increased ODC levels in Barrett's esophagus, 
chemopreventive intervention trials with ODC inhibitors, for instance alpha-
diflouromethylornithine, were inconclusive as to whether or not changes in the 
polyamine contents would be induced in Barrett's mucosa (119, 120). A 
complicating factor may be a defective ODC - polyantine pathway, which may 
also explain the poor correlation between ODC activity and polyamine levels 
(121, 122). 
2.3 Proliferation 
Proliferation of tissues can be assessed by several methods. Through metabolic 
labeling, tritiated thymidine or 5-Bromodeoxynridine (BrdU), an analogue of 
thymidine, can be incorporated into the DNA during S-phase of the cell cycle, 
and proliferating cells can be identified. Early studies using these 
autoradiographic methods showed expansion of the proliferative compartment in 
Barrett's esophagus compared to other columnar epithelia (123, 124). 
Alternatively, proliferation can be assessed by immunohistochemistry using 
antibodies recognizing antigens which are expressed in the nucleus during 
proliferation. PCNA (Proliferating Cell Nuclear Antigen) and Ki-67 are such 
antigens. PCNA, a 36 kDa molecule, serves as a cofactor for DNA polymerase 
delta in both S-phase and unscheduled DNA synthesis associated with DNA 
repair. Since PCNA has a 20 hour half life, it can also be found in non cycling 
cells, i.e., GO phase. The Ki-67 antigen is expressed in the nuclei during late G 1, 
S, G2, and M phases of the cell cycle, but not in GO phase and is therefore a 
more precise marker for estimating proliferation. Assessment of these markers in 
Barrett's esophagus showed that proliferation is increased in intestinal type of 
metaplasia even when dysplasia is absent. Interestingly, with increasing dysplasia 
the fraction of proliferating cells and the proliferative compartment increases 
further (125, 126). Eventually, in high grade dysplasia luminal epithelial cells 
show proliferative activity. (123, 125, 127, 128). Reid et aI., used multi-
parameter flow cytometry to simultaneously measure DNA content and cycling 
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cells, which allowed him to estimate the fractions of cells in GO, Gl, S and G2M 
phase. In this study for instance an increased number of cells is found in Gl 
phase early on during the neoplastic progression (126). 
2.4 Growth Factors 
Growth factors are important for regulation of cell differentiation and 
proliferation. Abnormal expression of growth factor receptors, such as EGF-R 
(Epidermal Growth Factor) and ligands such as EGF (Epidermal Growth Factor) 
and TGF-Alpha (Transfonning Growth Factor-Alpha) are associated with 
mitogenesis and carcinogenesis (129). In Barrett's esophagus expression of EGF-
Rand TGF-Alpha but not EGF is increased in intestinal type metaplasia 
compared to the other types of metaplasia. Both markers are also elevated in 
dysplasia and in esophageal adenocarcinomas (113, 130-134). 
2.5 Oncogenes 
Abnormal expression of (proto)oncogenes is involved in the transformation of 
normal tissues into malignancy (135). Many oncogenes studied in Barrett's 
esophagus did not yield specific data, while some need more extensive evaluation. 
For instance, in a small series of patients increased H-ras expression has been 
observed in high grade dysplasia and adenocarcinoma (136). The proto-oncogene 
product C-erbB2 is a glycoprotein which shows high homology with the 
epidermal growth factor receptor, EGF-R. Like EGF-R, C-erbB2 can be activated 
through ligands and in tum activate pathways in the cytoplasm involved in cell 
differentiation and proliferation (137, 138). Although, C-erbB2 expression has 
been found to be correlate with survival of patients with esophageal 
adenocarcinoma, the proportion of C-erbB2 expressing cases in the different 
studies varied between to to 73 % and hence this protein needs to be further 
evaluated (139-142). 
2.6 P53 and other tumor suppressor geues 
In contrast to an oncogene, the function of a tumor suppressor gene is only 
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disrupted in case both alleles are defective. This condition is usually met by loss 
of one allele and functional inactivation of the other. Tumor suppressor gene 
alterations can be studied by a variety of techniques. Gene mutations can be 
studied by PCR (Polymerase chain reaction) and sequence analysis or SSCP 
(Single Strand Conformation Polymorphism) analysis. allelic loss by RFLP 
(Restriction Fragment Length Polymorphism) analysis. 
The p53 tumor suppressor protein was detected in 1979 by Lane and Crawford 
(143). Though formerly regarded as an oncoprotein, the main function of p53 is 
that of a tumor suppressor (144, 145). Although p53 is a tumor suppressor, it can 
display oncogene-like behavior, because mutant p53 molecules may bind to and 
inhibit wild type p53 function. Under normal circumstances Wild-type p53 plays a 
limited role in cell cycle control. In cells with genomic damage, accumulation of 
high levels of wild-type p53 in the cell nucleus results in a prolonged G 1 phase of 
the cell cycle. The extended G 1 phase consequently delays replication in damaged 
cells, which facilitates DNA repair (146, 147). Another unique property of this 
protein is that mutant forms acquire conformational changes which prolong half 
life, resulting in accumulation of mutated p53 protein in cells (148, 149). Wild 
type as well as mutated p53 protein are detectable by immunohistochemistry as 
long as a sufficient amount of protein is retained (150). 
In Barrett's esophagus and esophageal adenocarcinoma p53 aberrations have been 
extensively documented. Although the applied methodologies vary, the findings 
show a certain consistency. The prevalence of p53 protein accumulation as 
determined by immunostaining in adenocarcinomas ranges between 53-87 % 
(151-157). In esophageal adenocarcinomas p53 (17p) allelic loss is found in 55% 
to 100% of cases (152, 158-160), and p53 gene mutations in 8% to 89% of cases 
(159, 161-166). In esophageal adenocarcinomas no correlation was found between 
p53 protein accumulation and clinicopathological and prognostic factors (167). 
Nevertheless, in Barrett's esophagus the frequency of p53 alterations increases as 
the epithelium becomes more dysplastic (151, 154-156, 168). The prevalence of 
abnormal p53 reaches up to 89% in high grade dysplasia. Since aberrant p53 can 
be found in non dysplastic Barrett's esophagus and cases with low grade dysplasia 
(table 2), p53 mutations is considered one of the earliest genetic events during 
malignant transformation of Barrett's esophagus. Several studies have shown that 
in resection specimens mutations in the adenocarcinoma correspond with those in 
surrounding Barrett's epithelium (162, 164, 165). Interestingly, p53 assessment 
combined with DNA cell sorting showed that p53 mutations occur in diploid 
cells, suggesting that these precede aneuploidy. Only a few follow up studies 
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have been published. Younes et aI., performed a follow-up study of 24 patients 
with Barrett's esophagus. After a follow-up period of 9-166 months, three cases 
of Barrett's esophagus had progressed into high grade dysplasia, two of which 
had low grade dysplasia but p53 immunoreactivity in their initial biopsies (155). 
Table 1. P53 proteill immllnoreactivity ill adenocarcinomas complicatillg Barrett's esophagus. 
Total # of Cases with P53 
adenocarcinomas 
Blount et aL, 1992 13 8 (62%) 
Ramel et aI., 1992 15 8 (53%) 
Younes et al., 1993 8 7 (87%) 
Krishnadath et ai., 1994 24 20 (83%) 
Flljou et aI., 1994 62 41 (66%) 
Moore et aI., 1994 19 11 (58%) 
Hardwick et. al., 1994 30 16 (53%) 
Recently, Schneider et al, documented the prevalence p53 gene mutations in 50 
esophageal adenocarcinomas, and in 48 cases of Barrett's esophagus, 32 without 
dysplasia, 13 indefinite for or with low grade dysplasia and 3 with high grade 
dysplasia. P53 gene mutations were found in 46% of the adenocarcinomas. Only 
in one case of Barrett's esophagus, which was highly dysplastic, was a p53 gene 
mutation found (165). After a mean follow-up period of 2.2 years non of the 
Barrett's esophagus patients developed adenocarcinoma. Although p53 seems to 
be a promising prognostic marker, malignant transformation occurred without p53 
protein accumulation in one follow-up study which implies that in a subset of 
carcinomas malignant progression is initiated following alternative pathways. 
Table 2. P53 protein immulloreactMty ill Barrell's esophagus 
Ramel et at 
Younes et al 
Krishnadath et al 
Rice et at 
No dysplasia 
1121 (5%) 
0/53 (0%) 
3/50 (6%) 
Indefllow grade 
2/13 (15%) 
4/44 (9%) 
12/43 (28%) 
0127 (0%) 
high grade 
2/13 
519 
8/9 
18/26 
(15%) 
(55%) 
(89%) 
(89%) 
Another potentially important tumor suppressor is the APC gene. Allelic loss of 
the 5q chromosomal region harboring the APC gene, was found in 66-77 % of 
esophageal adenocarcinomas (158, 169). Of interest is that during clonal 
evolution 17p was found to precede 5q allelic loss (170). Recent, investigations of 
APC allelic loss in esophagectomy specimens showed identical APC gene 
alterations in adenocarcinoma and in Barrett's epithelium surrounding the 
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adenocarcinoma (171). Despite the high frequency of 5q allelic loss in the APC 
region as observed several studies, APC gene mutations were only sporadically 
found in esophageal adenocarcinomas (172). Possibly another gene or genes on 
5q, distinct from APC, are involved. 
Other allelic losses of familiar tumor suppressor genes have been found for the 
mutated colon carcinoma (MCC) gene in 63%, for deleted in colon carcinoma 
(DCC) gene in 24% and for the retinoblastoma (Rb) gene in 48% (158, 169). 
2.7 Numerical and structural chromosomal aherrations 
A variety of cytogenetic and molecular biological techniques is available for 
detecting numerical and structural chromosomal abnormalities. The general idea 
is that these methods will lead to the detection of chromosomal regions which 
may harbor genes involved in cell cycle regulation and carcinogenesis. Such 
genes may be onco- and tumor suppressor genes, cell cycle and cell death 
(apoptosis) regulating genes, growth factors, genes coding for transcription and 
signal transduction factors and cell adhesion genes. In esophageal 
adenocarcinomas many aberrant chromosomes and chromosomal regions have 
been identified, whereas the number of genetic aberrations in Barrett's esophagus 
is limited. The most frequently documented numerical chromosomal aberration in 
Barrett's esophagus and esophageal adenocarcinomas is loss of the Y-
Chromosome (173-179). In esophageal adenocarcinoma Y-chromosome loss was 
found in 31 to 93 % of cases. In Barrett's esophagus, for instance Garewal et aI., 
noticed Y-Ioss in 7110 cases. In chapter 5 of this thesis the frequency of Y-
chromosome loss in Barrett's increased along with grade of dysplasia and all 
cases of high grade dysplasia showed Y- chromosome loss. Although Barrett's 
esophagus and esophageal adenocarcinoma occur more frequently in men, no 
specific onco- or tumor suppressor genes have been assigned to the Y-
chromosome. Perhaps, as genetic instability increases during malignant 
transformation of Barrett's esophagus, Y-chromosome loss randomly occurs. 
Nonetheless, the Y-chromosome may harbor genes involved in signal transduction 
or cell cycle regulation, which in a more subtle fashion may influence cell 
transformation. 
Other frequent numerical aberrations in esophageal adenocarcinomas are over 
representation of chromosomes 8, 14 and 20 and loss of chromosomes 4, 17, 18 
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and 21 (174, 175, 177, 179). Karyotyping revealed frequent structural 
rearrangements in esophageal adenocarcinomas in the Ip, 3q, llpI3-15, and 22p 
regions (174, 179). Loss of heterozygosity studies showed high frequencies of 
17p (100%) and 5q (80%) allelic loss in adenocarcinomas (152, 160, 170). 17p 
and 5q loss were also seen in Barrett's esophagus with high grade dysplasia. 
Interestingly in Barrett's esophagus 17p preceded 5q loss (170). In approximately 
60% of esophageal adenocarcinomas structural loss of 9p and in 40% of Ip, 
13q, and 18q was observed (160). 
2.8 Aneuploidy 
DNA flow cytometry (DNA-FCM) is the method of choice for measuring DNA 
cell content. In addition, DNA-FCM may serve to determine the fraction of cells 
in different phases of the cell cycle, such as resting cells in GO and G 1, cells with 
active DNA replication in S-phase and cells with doubled DNA content and in 
mitosis in G2M phase. Karyotyping and DNA in situ hybridization may also 
provide information on cell ploidy. Aneuploidy is found in esophageal 
adenocarcinomas with a frequency ranging from 79% to 100% (126, 141, 178, 
180-184). In several studies aneuploidy of esophageal adenocarcinoma was found 
to correlate with the presence of lymph node metastases and poor survival (141, 
184). 
Although data on aneuploidy in Barrett's esophagus have been inconsistent, 
aneuploidy and increased G2M/tetraploid populations seem to increase along with 
increasing dysplasia (126, 178, 180-183, 185-189). Most discordance between 
several studies can be explained by methodological differences. For instance, 
interpretation of a DNA FCM histogram depends on parameters chosen by the 
investigator. Other confounding factors are contamination with non-epithelial 
(diploid) cells and differences between fresh and paraffin embedded tissues. 
Convincing results have been published by Reid et al (126, 180, 182, 187). 
Aneuploidy and increased tetraploidy were not found in esophagitis, but in a low 
percentage of cases with intestinal type of metaplasia without dysplasia or 
indefinite for dysplasia, in a high percentage of cases with dysplasia and in all 
cases of adenocarcinoma (180). These findings were confirmed by others by 
DNA -flow or - image cytometry (181, 183), and DNA in situ hybridization with 
(peri-) centromeric DNA probes (178). Aneuploidy and increased tetraploidy have 
also been correlated with ultrastructural abnonnalities (186). In a prospective 
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follow-up study most (70%) patients with aneuploidy or increased tetraploidy in 
their initial biopsy specimens progressed toward high grade dysplasia or 
carcinoma. In contrast patients without DNA-FCM abnormalities did not develop 
high grade dysplasia or carcinoma (187). 
2.9 The E-Cadherin-Catenin Complex. 
The transmembrane 120 kDa glycoprotein E-Cadherin belongs to the family of 
calcinm dependent adhesion molecules (190, 191). TIle E-Cadherin gene has been 
mapped on chromosome l6q22.l (192). Cadherins play an important role in 
morphogenesis of tissues during embryogenesis (193). E-Cadherin is part of a 
larger system, and in addition to Catenins also interacts with Plakoglobin and a 
tyrosine kinase substrate, p120cas (194-196). As E-Cadherin is responsible for 
tight cellular connections in mature cells which arrange epithelial architecture, 
expression of E-Cadherin between epithelial cells is concentrated at tight 
junctions, adherens junctions and desmosomal regions (197). It has become 
apparent that homotypic E-Cadherin cell-cell mediated adhesion is structurally 
organized as a zipper (198). In malignancies, dissolution of cell-cell adhesions is 
the first step in invasion. There is substantial evidence that reduced expression or 
inhibited function of E-Cadherin leads to detachment of cells and increased 
invasiveness. For instance in vitro, monoclonal antibodies against E-Cadherin or 
blocking of E-Cadherin expression in canine kidney cells leads to transformation 
into an invasive phenotype (199). In the other direction, induction of E-Cadherin 
expression inhibits the invasive phenotype (195). In addition to its role in cellular 
adhesion, E-Cadherin is also involved in signal transduction via connections with 
Catenins and the actin cytoskeleton (200). Furthermore, aberrant Catenin 
expression may impair normal E-Cadherin function (201). The Catenin anchorage 
complex, which interacts with the cytoplasmic domain of E-Cadherin, consists of 
a heteromere of at least three proteins: Alpha-, Beta- and Gamma-Catenin. 
Alpha-Catenin a 102 kDa protein, homologous to Vinculin, is ubiquitously 
expressed in cells and mediates E-Cadherin connection to actin via Beta-Catenin 
(200-202). At least two isoforrns of Alpha-Catenin have been cloned (Alpha-
Neuro and Alpha- Epith-Catenin) (201). In turn, Beta-Catenin, a 92 kDa protein, 
homologous to the Drosophila armadillo gene and human plakoglobin, is directly 
linked to E-Cadherin (203, 204). The role and organization of Gamma-Catenin is 
not well understood, it appears that Gamma-Catenin has high homology to or 
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might be identical with plakoglobin (194, 205). 
Normal squamous epithelial cells, except in the most superficial keratinizing 
layer, intensely express E-Cadherin as well as Alpha- and Beta-Catenin on all 
cell-cell boundaries (206-208). Likewise, strong membrane bound expression of 
E-Cadherin and Catenins can be found at cell-cell boundaries of metaplastic 
columnar epithelia such as Barrett's esophagus (207-210). 
In esophageal adenocarcinomas aberrant E-Cadherin expression has been 
observed in 88% (45151) of the cases, 47% (24/51) of which showed 
disorganized E-Cadherin, whereas 41 % (21151) showed reduced expression 
(209). Aberrant expression correlated with poor differentiation and advanced 
stages of disease. Interestingly, northern blot analysis revealed in terms of size 
normal E-Cadherin and Alpha-Catenin mRNA expression in adenocarcinomas 
with normal but also in those with disorganized E-Cadherin expression. These 
findings imply that disorganized E-Cadherin expression with impaired E-Cadherin 
function might be indirectly induced by factors which interact with E-Cadherin. 
Beta-Catenin is such a potential factor. However, no literature data is available 
regarding Alpha- and Beta-Catenin expression in esophageal adenocarcinomas. In 
chapter 7, E-Cadherin, Alpha- and Beta-Catenin is investigated in 65 esophageal 
adenocarcinomas. Reduced E-Cadherin, Alpha- and Beta-Catenin expression was 
observed in between 60 and 75 % of cases. Reduced expression of E-Cadherin 
and Alpha-and Beta-Catenin correlated with unfavorable clinico-pathological 
parameters, such as poor differentiation grade, advanced stage disease and poor 
patient survival. 
2.10 CD44 and CD44 splice variants 
CD44 is a family of cell surface molecules, involved in intercellular interactions 
such as lymphocyte homing, lymphocyte activation, hemopoiesis, cell migration 
and metastasis, but also in binding of cytokines, hyaluronate and collagen (211, 
212). The CD44 gene has been mapped on chromosome IIp13 (213). The gene 
consists of at least 20 exons, 10 of which (exons 1-5 and 16-20) encode for the 
standard form of CD44 (CDst). At least ten remaining exons are subjected to 
alternative splicing. Differential expression of these exons give rise to several 
CD44 isoforms (214-216). The structure of the CD44 glycoprotein is complex. 
Its standard form (CDST), a 85-90 kDa glycoprotein, is involved in the functions 
mentioned above. So far, specific ligands which interact only with the variable 
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regions, have not been identified. In the first experiments which led to the 
discovery of splice variants, monoclonal antibodies raised against membrane 
epHopes of a metastasizing rat pancreatic cell line transiently inhibited the 
metastatic potential of these cells (217, 218). The cDNA sequence encoding the 
epHope recognized by one of these antibodies, appeared to be part of the exon 
encoding the v6 variant (216). Transfection experiments with cDNA partly coding 
for v6 conferred metastatic potential to a non metastatic rat pancreatic cancer cell 
line (219). TIle application of monoclonal antibodies raised against the transfected 
epitope blocked metastatic potential of the transfected cell line (220). hI various 
malignancies expression of several CD44 splice variants, such as 5v, 6v, 7v, 8v 
and 9v, has been related with increased tumor invasiveness, metastatic potential 
and patient survival (221-228). Nonetheless, splice variants are not exclusively 
expressed in metastatic cells. The epithelial CD44 version (CD44E) besides 
standard CD44 also includes the 8-9 and 10 variable exons (229-231). CD44 
isoforms are typically expressed by cells that participate in dynamic processes, 
such as normal tissue development, regenerative processes, innammation and 
wound healing. Thus normal expression of CD44 isoforms can be found in 
embryonic cells, activated T and B lymphocytes, and in proliferative zones of 
both squamous and columnar epithelium (232). Although the exact mechanisms 
are not yet known, regulated CD44 isoform expression presumably plays a major 
role in cell movement and cell-cell and cell-extra cellular matrix contacts (233). 
In metastatic cells genetic events may initiate expression of CD44-isoforrus, 
rendering cancer cells metastatic. 
Little literature data is available concerning CD44 and CD44 isoform expression 
in Barrett's esophagus and esophageal adenocarcinomas. In chapter 8, a panel of 
tissues from Barrett's esophagus, esophageal adenocarcinomas and lymph node 
metastases was investigated for CDST and CD44v6 expression. Expression of 
CDST in Barrett's esophagus correlated with grade of dysplasia and proliferation, 
whereas increased CD44V6 expression appeared to occur early during neoplastic 
progression. Interestingly, in the esophageal adenocarcinomas increased CD44V6 
expression tended to be correlated with worse five year survival. 
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Chapter 3 
Aim of the Study and Introduction to the Papers 

3.1 From Barrett's esophagus to esophageal adenocarcinoma and 
metastasis. 
A major difficulty concerning Barrett's esophagus is whether to screen or not to 
screen (70). Only a fraction of Barrett's esophagus cases will progress to 
malignancy. Consequently, screening of all cases of Barrett's esophagus' for 
malignant degeneration is not efficient. However, patients with early stage disease 
as discovered in screening programs have significantly better prognosis than 
patients with advanced stage disease. Therefore, a screening approach, which can 
predict in an early phase which Barrett's esophagus will progress to malignancy 
is of paramount importance. At present biological parameters with this potential 
has not been found. It should be realized that, malignant progression in Barrett's 
esophagus may follow several pathways in which many different factors are 
involved. Histopathological assessment of dysplasia, although to a certain degree 
subjective, seems to give the best reflection of the level of progression in a 
lesion. Any expectation to be able to replace histological assessment with a single 
biological parameter is, given the complexity of the process involved, not 
realistic. As important as identifying Barrett's esophagus patients at risk for 
neoplastic transformation is improving treatment of patients with esophageal 
adenocarcinoma. As the incidence of esophageal adenocarcinomas is rapidly 
rising, optimal care and treatment of this group of patients is of increasing 
importance. In general, patients with esophageal adenocarcinoma have a poor 
prognosis. The extent and aggressiveness of disease are important parameters for 
selecting treatment strategies. The tendency of esophageal adenocarcinomas to 
metastasize in early phase of disease, sometimes with only limited invasion of the 
esophageal wall, is poorly understood. Histopathologically, esophageal 
adenocarcinomas are heterogeneous, varying from well differentiated to 
undifferentiated phenotypes. Nevertheless, grade of differentiation seems not to 
be a good parameter for behavior of these malignancies. Although stage indirectly 
determines the aggressiveness of disease and accurately predicts long term 
survival of patients, it does not yield specific information about the intrinsic 
mechanisms which are involved in tumor behavior. 
3.2 Aim of the study 
The aim of this study was to assess the potential role of a number of events, 
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related to carcinogenesis in the evolution of Barrett's esophagus towards 
esophageal adenocarcinoma and metastasis. The information would help us to 
understand how this cancer develops and how metastases occur, and pointly at an 
early stage to detect which benign lesions might be prone for malignant 
progression, and which carcinomas tend to metastasize. Parameters were chosen 
which are related to molecular genetic events, cellular proliferation, and 
intercellular adhesion. Each of these factors plays a role in neoplastic 
progression. As the progression of Barrett's esophagus towards adenocarcinoma 
may take up to several decades, not a longitudinal but a trans sectional approach 
was used. For such an approach archival material collected from endoscopically 
surveyed Barrett's patients and surgical resection specimens of patients with 
esophageal adenocarcinoma provides an ideal basis. 
3.3 Introduction to the papers 
Chapter 4: 
"Detection of genetic changes in Barrett's adenocarcinoma and Barrett's 
esophagus by DNA ill sifll hybridization and immunohistochemistry. " 
The main goal of this paper was to screen a pilot of archival resected esophageal 
adenocarcinomas for common numerical chromosomal aberrations, aneuploidy, 
proliferation and p53 protein accumulation. By immunohistochemistry and the 
application of in situ hybridization with DNA probes on tissue sections, both the 
adenocarcinoma as the adjacent Barrett's esophagus in the resection specimens 
could be evaluated. The findings in this paper formed the basis for the next 
studies. 
Chapter 5: 
"Accumulation of p53 protein in normal, dysplastic and neoplastic Barrett's 
esophagus. 1/ 
In this paper the intention was to determine the frequency of p53 protein 
accumulation in esophageal adenocarcinoma and to investigate whether aberrant 
p53 is a prognostic parameter for neoplastic progression in Barrett's esophagus. 
By immunohistochemistry on paraffin sections, p53 protein accumulation was 
studied in a large penal of Barrett's esophagus with varying degrees of dysplasia 
and in a number of esophageal adenocarcinomas. 
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Chapter 6: 
''Accumulation of genetic abnormalities during neoplastic progression in Barrett's 
esophagus. " 
In an earlier study (chapter 4), Y-chromosome loss and aneuploidy were found in 
a subset of esophageal adenocarcinomas and in Barrett's esophagus adjacent to 
these carcinomas. In this study the meaning of these aberrations was further 
investigated. In the adenocarcinomas the frequencies of Y-loss and aneuploidy 
were detennined in archival resection specimens. In cases of Barrett's esophagus 
not related to adenocarcinoma the prognostic value of Y-loss and aneuploidy was 
studied. In situ hybridization with DNA probes on archival tissues allowed us to 
evaluate these genetic aberrations with respect to grade of dysplasia in a series of 
biopsy specimens of patients with Barrett's esophagus. 
Chapter 7: 
"E-Cadherill, Alpha- and Beta Catenin e~pression ill Barrett's adenocarcinoma." 
The goal of this study was to investigate expression of several members of the E-
Cadherin-Catenin complex in esophageal adenocarcinoma and to evaluate the 
results against clinico-pathological criteria and patient survival. 
Immunohistochemistry was applied to a series of archival resection specimens and 
patient follow-up data was analyzed. 
Chapter 8: 
"CD44st and CD44v6 splice varia/II e.lpressioll ill Barrett's esophagus and 
Barrett's adenocarcinoma. " 
In this paper upregulated expression of CD44st and CD44v6 was investigated in 
esophageal adenocarcinomas to detennine whether these parameters are 
prognostic for aggressive tumor behavior. In Barrett's esophagus the prognostic 
value of upregulated CD44st and CD44v6 expression for malignant progression 
was evaluated. Immunohistochemistry was applied to archival material, consisting 
of esophageal resection specimens with adenocarcinomas and a series of archival 
biopsied material of patients with Barrett's esophagus. Data was evaluated against 
clinico-pathological parameters of the adenocarcinomas, and against dysplasia and 
proliferation rate in Barrett's esophagus. 
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Chapter 4 
Detection of Genetic Changes in Barrett's Adenocarcinoma and 
Barrett's Esophagus by DNA in Situ Hybridization 
and Immunohistochemistry. 
K.K. Krishnadath, H.W. THanus, J.C. Alers, 
A.H. Mulder, and H. van Dekken. 
Published in: Cytometry 1994;15: 176-184 

4.1 Abstract 
We have investigated the occurrence of chromosomal DNA and cell cycle related 
protein cbanges in Barrett's epithelium and adenocarcinoma. The presence of 
numerical chromosomal aberrations was studied by applying non-isotopic in situ 
hybridization (ISH) with (peri-)centromeric DNA probes, specific for 
chromosomes 7,8, 17, and Y, to routinely processed tissue sections of five cases 
(4 male , 1 female) of Barrett's adenocarcinoma and adjacent Barrett's 
epithelium. Cell cycle related protein expression was studied by 
immunohistochemistry (IHC) for p53 protein and the Ki-67 antigen (Mib-l) in 
subsequent sections. P53 protein overexpression was found in 3 of the 5 tumors. 
Over representation of chromosome 8 and loss of chromosome 17 were found in 
two adenocarcinomas, both also negative for p53 protein overexpression. Y-loss, 
mostly clonal, was detected in 3 of the 4 male adenocarcinomas and 2 cases of 
adjacent Barrett's epithelium. One tumor had both areas of over representation 
and loss of the Y chromosome. All Barrett's adenocarcinomas appeared to 
contain aneuploid cell populations. No relation was found between cell 
proliferation characteristics and chromosomal aberrations. We conclude that ISH 
with chromosome specific DNA probes can be applied for the assessment of 
potentially important numerical chromosome changes in Barrett's esophagus. 
Further, the combination of IHC and ISH is useful for evaluation of specific 
genetic events. 
4.2 Introduction 
In Barrett's disease the stratified squamous epithelium of the distal part of the 
esophagus is replaced by columnar epithelium, a process called metaplasia(l, 2). 
This condition is associated with a 30 to 40 times increased risk of developing 
esophageal adenocarcinoma (3, 4). Even after surgical resection and! or 
radiotherapy and chemotherapy, Barrett's adenocarcinoma has a poor 
prognosis(5). Early diagnosis of malignancy in Barrett's esophagus is essential 
for optimal treatment and better prospects for the patient. Therefore a better 
understanding of the underlying mechanisms of carcinogenesis in Barrett's 
epithelium is of great importance. 
The progression to malignancy in Barrett's epithelium is a multistep process: 
Metaplasia progresses to dysplasia and eventually to adenocarcinoma. This 
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neoplastic transformation is related to major genetic changes ultimately 
progressing into malignancy (6). The correlation between aneuploidy and 
histological diagnosis of dysplasia or carcinoma has been well demonstrated in 
prospective studies by flow cytometric techniques (7, 8). However, little is 
known about the specific chromosomal aberrations. Karyotyping revealed 
frequent loss of the V-chromosome in Barrett's epithelium (9), while structural 
rearrangements were found in the llp13-15 region in Barrett's adenocarcinoma 
(10). 
P53 gene mutations and protein overexpression has been demonstrated in 
Barrett's adenocarcinomas, and in Barrett's esophagus (ll, 12). Genetic analysis 
demonstrated a high incidence of loss of heterozygosity (LOH) of multiple tumor 
suppressor genes, including p53, in Barrett's adenocarcinomas (13). Cytogenetic 
studies of other gastrointestinal malignancies, i.e., gastric adenocarcinomas 
revealed frequent loss of the Y -chromosome and over representation of 
chromosomes 7, 8, 9 and 12 (14, 15). In colon carcinomas a frequent loss of 
chromosomes 18, 22, Y and gain of the chromosomes 7, 8, 12, 13, 20 was 
shown (16). 
The cytogenetic study of solid tumors by karyotyping is often unprofitable and 
strenuous (17). In contrast, analysis of numerical chromosomal aberrations by 
non-isotopic in situ hybridization (ISH) to isolated nuclei of solid tumors has 
proved to be efficient and successful (18-22). ISH on formalin-fixed paraffin-
embedded tissue sections created the possibility of chromosomal analysis in 
archival material (23-26). The latter ISH technique has the great advantage of 
preserved morphology leaving different cell types distinguishable and enabling 
analysis of the tumorigenic cells only (27). 
In this study we analyzed the presence of numerical chromosomal aberrations by 
applying non-isotopic in situ hybridization with (peri-)centromeric DNA probes, 
specific for chromosomes 7, 8, 17 and Y, to five archival cases of Barrett's 
adenocarcinoma and adjacent Barrett's epithelium. In each case cardia tissue and 
leucocytes were used as controls. Karyotyping of all five specimens had failed to 
produce analyzable metaphases of Barrett's epithelium or adenocarcinoma cells. 
Cell proliferation was estimated by immunolabeling of the Ki-67 antigen through 
it's reactivity with Mib-I (28). Immunohistochemistry was also used to detect 
overexpression of the p53 protein. 
4.3 Materials and methods 
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4.3.1 Tissue preparation 
Paraffin-embedded material, obtained between 1990 and 1991, of five 
esophageal-cardia resection specimens containing adenocarcinoma in Barrett's 
epithelium was used. In situ hybridization (ISH), immunohistochemistry (!HC) 
and flow cytometry were performed on subsequent tissue sections. For ISH and 
IHC, 4 I'm sections were sliced from paraffin blocks containing tumor andlor 
Barrett's epithelium. Sections were adhered to amino alkyl-coated slides (Sigma, 
St Louis, MO) for better preservation of tissue architecture. 
Table 1.' Tumor/Pat/em ill/ormatioll 
Case Age/Sex Tissue Stage l Grade1.3 
#1 75/F Adenocarcinoma TlNOMO Gl 
Epithelium High 
#2 69/M Adenocarcinoma T3N1MO G3 
Epithelium High 
#3 65IM Adenocarcinoma T3N1Ml G3 
Epithelium Moderate 
#4 6l1M Adenocarcinoma T3N1Ml G3 
Epithelium Low 
#5 70IM Adenocarcinoma T3N2MI G3 
Epithelium Moderate 
1 TUmor stagillg by TNM classification; Tl: TUmor il1ftltralioll ill submucosa. 12: ill muscularis 
propriae, T3: ill advemitia alld beyond. NO: lymp/le !lode metastasis are absellt, Nl,' regiollallympll 
/lode metastasis, N2: distallt lymp/te node metastasis, MO: I/O organic metastasis, MI: organ 
metastasis. 
2 Histopathological grade of dijferemiatioll ill tumor: GJ-G2-G3 = good-moderate-poor 
dijferemialioll. 
J Histopathological grade of dysplasia ill Barrell's epithelium: low-moderate-higll. 
4.3.2 Probe and probe labeling 
A probe set specific for chromosomes 7, 8, 17, and Y was selected. Selection 
criteria were based on literature data considering numerical (and structural) 
aberrations in esophageal and other gaslro-intestinal tumors (2,1O,11,12,41). The 
(peri}centromeric repetitive satellite DNA probes were labeled with biotin-14-
dATP by nick translation of complete plasmid DNA according to manufacturer's 
directions (BRL, Gaithersburg, MD). DNA probes were stored at -20°C. 
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4.3.3 In Sitn Hybridization 
The in situ hybridization procedure was performed as described by van Dekken 
et al. (27). Briefly, after deparaffinizing of the tissue sections in xylene, 
endogenous peroxidase activity was blocked with 0.3 % H,O, in methanol. 
Enhancement of tissue permeability was achieved by proteolytic enzyme digestion 
(pepsin: Sigma, 4 mg/ml in 0.2 M HCI) for 15-20 minutes at 37 'C. Before 
applying the probe set, the optimal digestion time for each tumor was determined 
by a pepsin time series (5, 10, 15 and 20 minutes). 
Tissue DNA was heat denatured for 2 minutes in 70% formarnide in 2xSCC (pH 
7.0), followed by dehydration in an ethanol series. Chromosome specific 
repetitive DNA probes were denatured for 5 minutes at 70 'C in a hybridization 
mixture, containing: 1-2 I'g/ml probe DNA, 500 I'g/ml sonicated herring sperm 
DNA (Sigma), 0.1 % Tween-20, 10% dextran sulphate, and 60% formarnide in 
2xSSC at pH 7. The probe mixture was then applied to the sections and 
incubated overnight at 37 'C. Then the slides were washed in 60% formamide in 
2xSSC (pH 7.0) at 42 'C. 
Histochemical detection was perfornled by immunoperoxidase staining. Slides 
were subsequently incubated for 30 minutes at 37 'C with mouse-anti-biotin 
(Dakopatts, Glostrup, Demnark), biotin-labeled horse-anti-mouse (Vector, 
Burlingame, CAl and with avidin-biotin-complex (Vectastain Elite ABC Kit). 
Visualisation was achieved with 0.05% H,O" 0.5 gIl DAB, 0.1 M imidazole in 
PBS (Phosphate Buffered Saline). The signal was amplified with 0.5% CuS04 in 
0.9% NaCI. Slides were rinsed in distilled water and counterstained with 
hematoxylin. Finally, slides were dehydrated in ethanol, cleared in xylene and 
mounted in Malinol (Chroma-Geselschaft, K6ngen, Germany). 
4.3.4 ImmunoWstochemistry 
For immunostaining of p53, DO-7 (Dakopatts) was applied, diluted 1125 in PBS 
for overnight incubation. This monoclonal antibody recognizes an epitope in the 
N-terminus, residing between amino acids 35 and 45 of the human p53 protein. 
Primary labeling of the Ki-67 antigen was performed with a monoclonal 
antibody, Mib-I (Immunotech, Marseille, France), diluted 1125 in PBS. The 
monoclonal Mib-I reacts with native Ki-67 antigen and recombinant fragments of 
the Ki-67 molecule (28). When compared with staining of Ki-67 on fresh (frozen) 
tissues, Mib-I shows corresponding staining of proliferating cells in formalin-
fixed paraffin embedded tissues (29). For negative controls the primary 
antibodies were replaced by PBS. 
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Before immunolabeling enhancement of p53 protein staining by DO-7 was 
achieved by heating slides submerged in distilled water in a microwave (700 W) 
at 95°C for 2x5 minutes with an interval of 1 minute. During this interval fluid 
level was checked and restored. The same procedure was followed for Ki-67 
staining by Mib-I, using citrate buffer (10 mM citric acid monohydrate, pH 6.0) 
instead of distilled water. Immunohistochemistry was performed using the routine 
ABC-immunoperoxidase method (Vector). 
4.3.5 DNA flow cytometry 
DNA content of the paraffin material was measured, basically as described by 
Hedley et al. (30). Tumor, dysplastic and cardia regions were selectively cut out 
of the paraffin blocks. Flow cytometry and analysis of the ethidium bromide 
(Sigma) stained nuclei from these areas was carried out using a Facscan (Becton 
Dickinson, Mountain View, Cal. 
4.3.6 Analysis 
Results of ISH with probes for chromosomes 7, 8, 17, and Y were evaluated on 
consecutive 4 I'm sections in previously defined areas. This approach was applied 
to reduce artefacts due to tumor heterogeneity and section thickness. Leucocytes 
on the same sections served as controls for hybridization quality, cardia cells 
were used as a tissue specific control. For each probe the number of solid DAB 
spots was scored (0, 1, 2, 3, 4, >4 spots) of 100 distinct, non-overlapping, 
single or side by side 4 I'm nuclear slices. Scoring was performed by two 
independent investigators. The counted spot distributions were compared, 
Figure 1: (A) Frequency distributions of tile hybridization spots, obtained by in situ hybridization 
(ISH) 011 4 11m tissue sectiol/s with (peri~)cel1lromeric DNA probes, speciftcfor chromosomes 7,8,17 
alld Y, ill Barrett's adenocarcinoma of patiellt #4. For each DNA probe the Jlumber of hybridization 
spots (0,1,2,3.4, > 4) was determined ill 200 lIuclei alld expressed as a percelllage, FOT each of the 
DNA probes a different spot distribllfioll was fOlllld. 171e chromosome 7 profile was taken "modal", 
based 01/ the flow cytometric DNA index. I1len a gaill can be seen for chromosome 8, whereas loss is 
found of 17. (B) Chromosome 8 DNA probe distribllliOll ill Barrett's adenocarcinoma (care.), 
Barrett's epithelium (epitlt.), normal cardia tissue and leucoC)'tes (blood) of patient #4. Strong 
hyperdiploidy (gain) of chromosome 8 is seell ill the adenocarcinoma. (C) III lite same case the 
chromosome 17 DNA probe distributioll shows loss of chromosome 17 ill the adellocarcinoma. (D) 
Spot distribllfioll of DNA probes 7, 8, 17 and Y ill Barrett's epithelium of case #5 reveals 11011-
complete loss of chromosome Y. (E) Spot pattem of the Y probe ill patielll #2 sholVs complete loss ill 
Barrett's epithelium, but 1I0t ill the tumor. Note the presence of nuclei with more thall olle copy of Y 
ill this tumor. (F) Spot distributiolls of the DNA probes III the adenocarcilloma oj patlem #3 shows 
loss of the Y chromosome. 
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averaged and plotted in bar histograms. Hyperdiploidy was estimated by 
determining the mean percentage of cells with more than 2 spots per nucleus for 
the autosomal probes (7, 8, and 17). In general, ISH hyperploidy was closely 
associated with the results of DNA flow cytometry. Therefore, in case multiple 
ISH aberrations occurred, the DNA probe distribution(s) that followed the flow 
cytometric profile most closely, was assigned "modal". For statistical analysis of 
the spot distributions the Kolmogorov-Smimov test was used (27). 
Cellular proliferation was estimated by determining the percentage of Ki-67 
positive cells. The percentages of both p53 and Ki-67 positive cells were 
established by serial counting of 200 cells in the same areas. Again scoring 
was performed by two independent investigators. 
Table 2: Results of iii situ hybridizatioll (ISH) with a sel oj chromosome specific repetitive DNA 
probes (7, 8, 17 alld y), DNA flow c)'/ometry, and immullohistocliemislry with DO-7 (P53) and Mib-l 
(Ki-67) a/five cases of Barrell's adenocarcinoma (A) alld epithelium (E). 
c"-'" Tissue Ki-671 P531 01' ISH· ISH' 
(%) (%) (p2%) aneuploidy aberrations 
#1 A 23% 78% 1.6151 18% 
E 27 48 1.6151 7 
If2 A 46 80 1.7/63 54 
E 15 21 1.7/40 19 -y 
#3 A 46 89 1.6116 I' -y 
E 17 0 1.0/- 3 
#4 A 55 0 1.9116 16 +8,-17,-Y 
E 21 0 1.0/- 2 
#5 A 40 0 2.0+2.7110" 17 +8,-I7,+Y/-Y 
E 15 0 1.0t- 3 -y 
I Kf-67: proliferation estimated by the percellfage of Ki-6? positive cells. 
2 Percellfage of p53 positive cells. 
J DNA Index by flow cytomelfY. (P2%) is percentage oj cells ill aI/euploid peak. 
-I Percelltage of hyperdiploid cells (> 2 spots per IIIlcleus) measured by ISH 
willi cellfromeric DNA probes for autosomal chromosomes 7, 8 and 17. 
s Kolmogorov-Smimov lesl: p < 0.01.6 Percellfage of cells ill two aneuploid peaks. 
4.4 Results 
We have used in situ hybridization (ISH) with a set of (peri-)centromeric DNA 
probes and immunohistochemistry (IRC) for cell cycle related proteins of five 
Barrett's adenocarcinomas and adjacent Barrett's epithelium. Normal cardia and 
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blood cells within the same specimen served as controls. One (female) tumor was 
well differentiated (GI), while infiltration was limited to the submucosa (TI). 
Four (male) poorly differentiated (G3) tumors infiltrated the adventitia (T3) and 
were metastatic. Grade of dysplasia in Barrett's esophagus was determined 
following a standardized classification (31). Two of the five adjacent Barrett's 
epithelia showed high grade dysplasia, two showed moderate and one low grade 
dysplasia. Surgical intervention was at a mean age of 68 (tab 1). ISH with 
specific centromeric probes for chromosomes 7, 8, 17 and Y, revealed a number 
of abnormalities in Barrett's adenocarcinoma as well as in Barrett's epithelium 
(tab 2). Specific chromosomal aberrations were found for chromosomes 8, 17 
and Y (Figs 1 and 2 ; P values <0.01). Over representation of chromosome 8 
and loss of chromosome 17 were found in the adenocarcinoma of patient #4 (figs 
IA-C and 2A-C) and of patient #5. Both cases were negative for 
immunoreactivity of p53. The ISH aberrations could not be distinguished in the 
control cells (figs IB-C). P53 overexpression was found in the other 3 cases of 
adenocarcinomas, two of which also had p53 immunoreactivity in the adjacent 
Barrett's epithelium, i.e. patients #1 and #2. TIlese two cases of Barrett's 
epithelium also contained significant amounts of aneuploid nuclei (tab 2). Loss of 
chromosome Y was seen in 3 of the 4 male tumors, and in the Barrett's epithelia 
of case #2 and #5 (figs lD-F and 2D-F; tab 2). This loss appeared to be clonal 
in both Barrett's epithelium and tumor of patient #5 (figs ID and 2E-F), and in 
the tumor of case #3 (fig IF). Tumor #5 also showed loss and over 
representation of the Y-chromosome in distinct areas (fig 2F). 
In cardia specimens the proliferation index (PI), as measured by Mib-I staining 
(Ki-67 antigen expression), was approximately 12%, while staining was limited 
to parabasal crypt cells (fig 3A). Slightly elevated Mib-I staining lVas found in 
Barrett's epithelium (fig 3B; tab 2). 
Figure 2(A) /1/ situ hybridization to a 41'.111 sectioll of Barrett's adenocarcinoma (arrows) of patiem 
#4 With Ihe chromosome 7 specific DNA probe. TIle ISH-related spots were visualized with 
immulIoperoxidaselDAB (black); hematoxylin was used as a COlillterstaill (grey). (8) In tile same 
fIlmor ISH with the chromosome 8 specific DNA probe shows mall)' hyperdiploid (> 2 SpOIS) nuclei ill 
strings of tumor celfs (arrows). (C) ISH wit" the chromosome 17 specific DNA probe reveals 
Ilumerous lIuclei wil" 0 or 1 spot. indicating loss of this chromosome (arrows: //lmor cells). (D) 
Barrett's epithelium oj patielll #2 demollstrates Y-Ioss ill the epithelial cells (arroll's), bur lIot in the 
stromal cells (arrowheads). (E) ISH with tile chromosome Y probe ill Barrell's epithelium oj case #5 
shows clol/al loss ill tile epithelial cells: Glands wit" (0) and without (If) this chromosome call be 
distinguished. (F) Cell Jluclei with alld without Y-loss are also seen ill the adellocarcilloma oj patielll 
#5. A 40x objecti\'e was Ilsed in A-F. 
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Figure 2 
(D,E,F) 
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In the low stage and grade carcinoma of patient #1 PI was 23% (fig 3C; tab 2). 
In 4 cases of adenocarcinoma, all four poorly differentiated and metastatic, PI 
was > 30%. No significant correlation was found between Y-Ioss or other 
chromosomal changes, and the PI. By means of ISH we were able to distinguish 
aneuploidy (>2 spots/nucleus) in all adenocarcinomas (range: 14-54%) and in 
two adjacent Barrett's epithelia (tab 2). In contrast, no significant percentages of 
ISH aneuploid cells were seen in cardia and leucocytes « 1 %). 
4.5 Discussion 
The analysis of numerical chromosomal aberrations by ISH in five Barrett's 
adenocarcinomas and adjacent Barrett's epithelium revealed specific changes for 
chromosomes 8, 17 and Y. Loss of the Y chromosome has been described in 
different gastro-intestinal malignancies(l4, 15, 32). Garewal found Y-Ioss in 
seven out of ten cases of Barrett's disease (9). Some investigators related Y-Ioss 
to a high proliferation rate of tissues, e.g. bone marrow cells (33). This is not 
supported by our study, since we did not see a correlation between proliferation 
rate (Ki-67) and loss of the Y chromosome. In a previous experiment combining 
proliferation markers and ISH no relationship was either found between loss of a 
chromosome (monosomy 9) and growth characteristics in bladder cancer cells 
(34). In our study proliferation rates in Barrett's esophagus were somewhat low, 
when compared with previous data(35). Our series however, is too small to draw 
conclusions. High copy numbers of chromosome 8 were found in two cases of 
Barrett's adenocarcinoma. Over representation of chromosome 8 has been 
reported in one case (out of four) of Barrett's adenocarcinoma (10). +8 is also 
seen in other malignancies of the gastrointestinal tract. In our set of tumors we 
did not detect the more common +7 abnormality. 
Figure 3(A) Immunohistochemical staining of the Ki-67 antigen with the mOl/oelonal olltihody Mib-l 
ill normal cardia tisslle, cOlllllerstailled with hematoxylin. Proliferation (Ki-67 alltigell expression) is 
limited to parabasal crypt cells (arrows). (8) Barrett's epithelium ojpaliellt #5 shows a slightly higher 
JlllIllber of Mib-J positi~'e ceUs. (C) Mib-l staillillg iii Barrett's adenocarcinoma oJpatielll #1 displays 
immulloreactivity ill a high number of (umor cells. (D) P53 illllllllllOllistochemistry with monoclollal 
DO-7 ill the same case shows positive reactioll ill a correspondillg pattern. Tisme was COllllterstailled 
with light Green. A lOx obj. lI'as used ill A-D. 
51 
Figure 3 
lA, B) 
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Figure 3 
(e, D) 
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The numerical changes of the Y chromosome appeared to be clonal in most 
cases. These cytogenetically different areas did not contain simultaneous clonal 
aberrations of the autosomal chromosomes. In one patient (#2: tab 2) 
chromosome Y was lost in the epithelium, while it was present in the tumor. 
This apparently indicates that Y-Ioss is not a subsequent event in carcinogenesis 
of Barrett's esophagus. Further, Barrett's adenocarcinomas tend to be 
heterogeneous (36), and clonal Y-Ioss might not be detected in this case due to 
tissue selection. These data suggest that presence of the Y chromosome has no 
relationship with tumor viability, as defined by proliferative and genomic features 
(21). 
Blount et al. found p53 overexpression combined with LOH of the 17p (p53 
gene) region in a high number of Barrett's adenocarcinomas (II). Our study 
demonstrates loss of chromosome 17 in two p53 negative tumors that contained 
multiple numerical chromosome aberrations (tab 2). We assume that in these two 
tumors one copy of chromosome 17 is lost while the p53 allele in the remaining 
chromosome is not expressed due to deletion, non-sense mutations or stop codons 
in the gene (37, 38). Since p53 allelic deletions have been observed in 92% of 
Barrett's adenocarcinomas (I I), the presence of 
immunohistochemically undetectable levels of normal p53 protein is less likely. 
Therefore, future experiments with DNA probes specific for the p53 region are 
needed to gain more insight in this matter. 
Barrett's epithelium is a unique model for studying carcinogenesis (39). 
Surveillance of patients with this disorder is by periodic endoscopy and biopsies. 
Surgical intervention is executed only in case of severe dysplasia or carcinoma. 
Unfortunately, cytogenetic study by karyotyping of surgical specimens of 
epithelial and cancerous tissue is often unsuccessful. Only one study is available 
about karyotyping in Barrett's epithelium (9). Karyotyping in our five cases 
yielded poor results. Interphase techniques such as in situ hybridization and 
immunohistochemistry demonstrate the possibility to study genetic events in 
Barrett's epithelium and adenocarcinoma. Future investigations with more refined 
DNA probe sets and larger panels of protein markers will possibly enable us to 
further identify genetic changes that are involved in tumorigenesis of Barrett's 
esophagus. 
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5.1 Abstract 
Accumulation of p53 protein was determined by immunohistochemistry in 
archival material of biopsy specimens from 102 patients with Barrett's esophagus 
with different grades of dysplasia, in 24 esophageal adenocarcinomas associated 
with Barrett's esophagus and in 23 cases of metaplastic epithelium adjacent to 
these carcinomas. Immunostaining for the p53 protein was found in 23/102 
(23%) cases of the Barrett's esophagus biopsies and in 12123 (52%) cases of 
Barrett's esophagus adjacent to adenocarcinoma. Significant correlations were 
found between grade of dysplasia and p53 immunoreactivity in both Barrett's 
biopsies without adenocarcinoma (p<O.OOI) and Barrett esophagus adjacent to 
adenocarcinoma (p<0.05). In the adenocarcinomas intense nuclear 
immunohistochemical staining for p53 was diffusely or focally present in 20/24 
(83%) of the specimens. In Barrett's esophagus p53 is a progression marker with 
high expression in high grade dysplasia (89%) and adenocarcinoma (83%). 
5.2 Introduction 
In Barrett's esophagus the stratified squamous epithelium of the distal esophagus 
is replaced by metaplastic columnar epithelium (1,2). Patients with Barrett's 
esophagus have a 30·40 fold increased risk of developing esophageal adeno-
carcinoma (3,4). Although adenocarcinoma in Barrett's esophagus is preceded by 
epithelial dysplasia, time course of progression of simple metaplasia into 
dysplastic Barrett's esophagus and ultimately into infiltrating adenocarcinoma is 
unknown. Furthermore, grading of dysplasia is to a certain extent subjective, 
leading to significant interobserver variation. Therefore, objective prognostic 
criteria predicting which cases of Barrett's esophagus will progress towards 
malignancy are of major importance. Previous immunohistochemical studies with 
proliferation markers already showed higher proliferation rates in dysplastic 
Barrett's esophagus (5) and abnormalities measured by DNA flow cytometry may 
precede malignancy (6). 
During the past years interest in tumor suppressor genes and proteins in 
(pre)malignant lesions has intensified. The appearance of the p53 tumor 
suppressor protein has been reported in a wide variety of malignant en 
premalignant conditions (7-14). P53 immunoreactivity has been reported in 62%-
87 % of esophageal adenocarcinomas, and in non dysplastic and dysplastic 
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Barrett's esophagus (15-18). 
Aim of the present study was to determine whether immunohistochemically 
detectable p53 protein accumulation occurs along with the development of 
dysplasia in Barrett's esophagus. 
5.3 Materials and methods 
5.3.1 Tissues 
P53 immunoreactivity was studied in archival biopsies taken between 1980 and 
1992 from 102 patients with Barrett's esophagus with various degrees of 
dysplasia but without adenocarcinoma. The number of biopsies per patient varied 
from one to twelve. Furthermore, paraffin-embedded tissue blocks from 24 
esophagus-cardia resection specimens with adenocarcinoma in Barrett's esophagus 
encountered between 1990 and 1992 were investigated. All patients had under-
gone cardiac-esophageal resection with gastric tube interposition. Surgery was 
performed at a mean age of 62 (range: 45-80). Non of the patients with 
adenocarcinoma had received chemo- or radiotherapy prior to surgery. One 
paraffin block containing adenocarcinoma was selected in each case. To 
determine the efficacy of p53 immunostaining in paraffin embedded tissues, 
immunohistochemistry for the detection of p53 protein was performed on 
corresponding fresh frozen samples of 20 of the adenocarcinomas. Barrett's 
esophagus adjacent to the tumor was found in 23 cases. In one case Barrett's 
esophagus was diagnosed in biopsy specimens prior to esophageal resection. 
Normal gastric-cardiac mucosa was used for control purposes. 
5.3.2 Histopathological criteria 
The histological sections were reviewed by two pathologists (A.H.M. and 
F.T.B.) Tumor staging was performed according to pTNM criteria. Barrett's 
esophagus was defined as columnar epithelial lining of the esophagus of at least 
three em proximal to the gastroesophageal junction. All cases had specialized 
columnar type. of metaplasia characterized by the presence of intestinal type of 
absorptive cells e.g., goblet cells. Dysplasia was graded into three categories 
following criteria revised by Reid et al. (19), Le.; negative, indefinite or low 
grade dysplasia and high grade dysplasia. Slides were coded and scoring of p53 
immunoreactivity was performed independent from grading sections. 
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5.3.3 Immunohistochemistry 
Cryostat sections (5 I'm) of fresh tissues were airdried aud fixed in acetone (-
20·C). After blocking of endogenous peroxidase activity aud rinsing in phosphate 
buffered saline (PBS, pH 7.4), p53 protein labeling was performed by staudard 
peroxidase-auti-peroxidase method (Dakopatts Z 259; Sigma P 2416, St Louis, 
MO). 
DO-7 (Dakopatts, Glostrup, Denmark), au Ig2b kappa monoclonal autibody 
recognizing au epitope in the N-tenninus between amino acids 35 aud 45 of 
human p53 protein, was used on formalin-fixed paraffin-embedded tissues. 
For paraffin sections au autigen retrieval method was applied (20). After 
blocking of endogenous peroxidase P53 labeling with DO-7 was performed by 
the streptavidin-biotin-complex procedure. The sections were preincubated for 15 
minutes at 37·C with 10% normal goat serum, diluted in PBS. DO-7, diluted 
1125 in PBS, was added for overnight incubation at 4 ·C. The negative controls 
were incubated with PBS only. The sections were subsequently incubated with 
biotinylated goat-auti-mouse IgG (1/400 in PBS, Dakopatts), rinsed aud finally 
incubated with a Streptavidin-biotinylated horseradish peroxidase complex 
(Dakopaus). Sections were developed for seven minutes in 3.3' diaminobenzidine 
tetrachloride. 
5.3.4 Microscopical evaluation 
Positive immunohistochemistry with the DO-7 p53 autibody was considered by 
moderate or intense brown nuclear staining. Cytoplasmic staining was not found. 
In a semi-quautitative scoring approach, two staining patterns were distinguished: 
A focal paUern, with > 10% of nuclei positive in clusters was mostly found in 
non dysplastic aud low grade dysplastic Barrett's esophagus. The focal staining 
was mostly confined to epithelial glauds (figure lA). A diffuse staining pattern 
with > 10% of positive nuclei scattered through the tissue was seen in most 
adenocarcinomas aud high grade dysplasia (figure lB). 
Figure 1 A: Focal immullohistochemical stail/illg of Ihe p53 protein with the mOl/oclol/al a1llibody DO-
7 ill a paraffin embedded sectioll of a Barrett's esophagus biopsy wilh low grade dysplasia. B: 
Moderately differelltiated esophageal adenocarcinoma showing a diffllse iml1lllllOslainilig pattem of 
tllmor cells. Both secliolls were coullterstailled by hematoxylin. A Jar objeclil'e was used. 
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5.4 Results 
P53 labeling by standard immunohistochemistry on unfixed frozen sections of 20 
Barrett's adenocarcinomas gave similar results as immunohistochemistry after 
antigen retrieval method on corresponding paraffin embedded formalin-fixed 
sections of these tumors. 
5.4.1 Normal cardia and esophageal mucosa 
Normal cardia tissue taken from the resection material was used for control 
purposes. All 24 cases were negative for p53. Weak nuclear staining with DO-7 
was sporadically seen in the basal layer of normal squamous epithelium. 
Table 1: P53 immullostaillillg ill biopsies from Barrett's esophagus 
dysplasia N Positive p53 
No n~50 3 (6%) 
Indefllow n~43 12 (28%) 
High 0=9 8 (89%) 
p<O.OOI" 
Total N~102 23 (23%) 
I) P-vo[ue as calculated by Trend test (21). 
5.4.2 Barrett's esophagus 
Immunohistochemical assessment of biopsy material from 102 patients with -
Barrett's esophagus without carcinoma revealed intense nuclear p53 staining in 23 
of 102 (23%) biopsies. A significant correlation was found between grade of 
dysplasia and p53 staining (Trend test: p<O,OOI, table I). Staining for p53 was 
found in eight of nine cases with high grade dysplasia, 12 of 43 (28 %) of cases 
with indefinite or low grade dysplasia, and in three of 50 (6%) cases of simple 
metaplasia, (table 1). Staining was focal in all non dysplastic, in eight 
indefinitellow grade dysplastic and in two high grade dysplastic cases (figure 
lA). In ten cases, 4 indefinitellow grade and six high grade, staining was diffuse. 
Table 2: P53 immullostaillillg ill Barrett's esophagus adjacent to adenocarcilloma. 
Dysplasia N Positive p53 
No n= 3 0 (0%) 
Indefllow n~ll 4 (36%) 
High n= 9 8 (89%) 
p<O.OSI) 
Total N~23 12 (52%) 
1) P-vafue as calculated by Trend res?l, 
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5.4.3 Barrett's esophagus adjacent to adenocarcinoma. 
Staining for p53 in Barrett's esophagus adjacent to the infiltrating tumor was 
performed in 23 cases. P53 staining correlated significantly with grade of 
dysplasia (Trend test p <0.05, table II). Eight of nine (89%) of the severely 
dysplastic cases showed diffuse staining. In four out of II (36%) cases with 
indefinite for or low grade dysplasia focal p53 staining was observed. P53 
immunostaining was not observed in the three non dysplastic epithelia adjacent to 
tumor. In a total of II cases of adjacent Barrett's esophagus p53 
immunoreactivity was not seen, four of which were adjacent to adenocarcinomas 
lacking p53 staining as well. 
5.4.4 Adenocarcinoma in Barrett's esophagus 
The 24 cases of adenocarcinoma in Barrett's esophagus were distributed 
according to tumor stage as shown in table three (table III). In 20 of 24 cases 
(83 %) diffuse (19 cases) or focal (I case) nuclear immunohistochemical staining 
for p53 was found (figure lB). Staining was similar in the three stage groups, 
with a slight preponderance of negative cases in the advanced tumors. Also no 
significant correlation was found between p53 staining and grade of 
differentiation. 
Table 3: P53 immtmostainillg ill adenocarcinomas ill Barrett's esophagus. 
Tumor slagel) N Positive p53 2) 
Tl n= 6 6 (100%) 
T2 n= 6 5 (83%) 
T3/4 n=12 9 (75%) 
Total N~24 20 (83%) 
1) Tumor stage accordillg to TNAI classification; Tl: filmor il1fi/fratioll ill 
submucosa, T2: ill muscularis propria, T3rr4: ill adl'elltitia and beyond. 
}) Focal or diffuse nuclear ill/munos/aluing. 
5.5 Discussion 
The study of different stages in carcinogenesis in a model which includes early 
stages of cancer development has important clinical implications. Barrett's 
esophagus might serve as a unique model in which early changes preceding full 
blown malignancies are encountered. Patients suffering from Barrett's changes 
are monitored by periodic endoscopies and biopsies, allowing longitudinal follow 
up studies. Although Barrett's esophagus may lead to malignancy, the course of 
the development of carcinoma in the individual can hardly be predicted by 
histopathology. Therefore tracing more objective parameters associated with 
dysplasia and reflecting the progression of malignancy is of paramount 
importance. P53 mutation, a common genetic event in many human malignancies 
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(7-14), might be such a parameter. Positive pS3 protein immunostaining is 
generally assumed to occur in case of gene mutations, which results in increased 
stability and consequently accumulation of mutated pS3 protein (22). Intense 
immunostaining with the DO-7 anti pS3 antibody has proved to be highly specific 
for mutated pS3 (23). 
In the present study nuclear pS3 protein staining was shown in 23 of 102 (23 %) 
biopsies from Barrett's esophagus with different grades of dysplasia and in 12 of 
23 (S2%) Barrett's esophagus adjacent to tumor. In these specimens pS3 staining 
correlated significantly with grade of dysplasia (p < 0,00 1 and p < O,OS 
respectively), with a high prevalence (89%) in high grade dysplasia. The number 
of cases with nuclear pS3 immunostaining in Barrett's esophagus in our study is 
somewhat higher than previously reported (16,17,18). Differences in the applied 
monoclonal antibodies and/or in the histochemical techniques used, may account 
for the discrepancies. 
Positive pS3 immunostaining in Barrett's esophagus with no or low grade 
dysplasia (16,17,18), may indicate that pS3 protein accumulation is an early 
event during carcinogenesis in Barrett's esophagus. Focally staining areas in 
these Barrett's esophagus may be associated with pS3 gene mutations, moreover 
these clones may be precursors of progressive lesions with ultimately diffuse pS3 
staining. PS3 gene mutations in non dysplastic and minimal dysplastic Barrett's 
esophagus were demonstrated by PCR and sequence analysis by Casson et al 
(24). Alternatively, increased amounts of wild type pS3 protein, resulting in 
positive immunostaining, were noticed in irradiated and highly proliferative 
tissues (2S,26). Since the DO-7 monoclonal also reacts with wild type pS3 
protein and proliferation rates are high in Barrett's esophagus (S), we cannot rule 
out that in a subset of cases immunostaining was a result of immunoreaction of 
DO-7 with wild type pS3. Furthermore, using monoclonal antibodies, certain 
conditions may give false negative results, e.g., when the epitope which is 
recognized by the DO-7 monoclonal antibody is mutated or inaccessible as a 
consequence of complex formation of pS3 with other proteins (27). On the other 
hand complete absence of pS3 protein (due to loss of both pS3 alleles, non-sense 
mutations or stop codons in the gene) would not be distinguishable from normal 
levels of wild type pS3 by immunohistochemical techniques; in both conditions 
staining would be negative. 
In the present study pS3 immunostaining was observed in 20 out of 24 (83 %) 
adenocarcinomas in Barrett's esophagus. In esophageal adenocarcinomas 
associated with Barrett's esophagus, Younes et a!., reported pS3 immunostaining 
in 87% (7 of 8) of cases. Additionally, in a follow-up series of 24 Barrett's 
esophagus patients three cases progressed to high grade dysplasia, two of which 
had pS3 immunostaining and low grade dysplasia in initial biopsy specimens (16). 
In the study of Blount et al., pS3 immunostaining was found in 62% (8 of 13) of 
esophageal adenocarcinomas, whereas allelic loss of the pS3 gene (17p) was 
detected in 92% of cases (IS). Although we did not find a correlation between 
tumor grade and pS3 protein accumulation, a trend between increasing pS3 
6S 
expression with reduced tumor differentiation was recently seen in a larger series 
(18). The absence of p53 staining in four tumors and in two cases of highly 
dysplastic Barrett's esophagus may indicate that malignant progression is possible 
without involvement of the p53 gene (28). 
P53 staining in tumor and in adjacent Barrett's esophagus do not necessarily 
correspond. In seven out of 19 patients Barrett's esophagus adjacent to p53 
positive tumor tissue showed no p53 immunostaining. None of these cases 
showed severe dysplasia. A similar observation was reported by Flejou et aI., 
who found that p53 immunostaining in Barrett's esophagus adjacent to p53 
positive adenocarcinomas was only present in case the epithelium was severely 
dysplastic (29). Recently Hardwick et aI., found positive p53 immunostaining in 
10 cases of dysplastic Barrett's esophagus, all adjoining p53 positive esophageal 
adenocarcinomas (30). In the present study four carcinomas did not show p53 
immunostaining. In all these cases adjacent Barrett's esophagus, regardless of 
degree of dysplasia, were negative as well. 
In conclusion, we found that p53 protein accumulates in Barrett's 
adenocarcinoma and in premalignant lesions, correlating with the degree of 
dysplasia. P53 immunostaining might therefore constitute a useful diagnostic tool. 
However, the value of p53 immunostaining in biopsies without high grade 
dysplasia in predicting the chance of development of carcinoma should be 
determined in prospective follow-up studies. 
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6.1 Abstract 
Sex chromosome status, ploidy and proliferation rate were evaluated in archival 
material of 73 Barrett's esophagus patients (48 male, 25 female). Diagnosis in 
esophageal mucosa samples ranged from intestinal metaplasia with no dysplasia 
to invasive esophageal adenocarcinoma; also four lymph node metastases were 
studied. Chromosomal and ploidy aberrations were determined by in situ 
hybridization with repetitive DNA probes specific for chromosomes Y, X and 1. 
Proliferation index (Ki-67 protein expression) was assessed by 
immunohistochemistry. Proliferation rate was elevated in all stages of dysplasia 
and in the adenocarcinomas. Aneuploidy (hyperdiploidy) and loss of the Y 
chromosome correlated with the advancing stages towards neoplasia (p<O.OOI), 
and reached high prevalences (70-100%) in high grade dysplasia and 
adenocarcinoma. Abnormalities of the X chromosome were not seen. These data 
suggest that in Barrett's esophagus genetic perturbations may be generated in 
relation to a high proliferation rate. 
6.2 Introduction 
Barrett's esophagus is a condition in which the stratified squamous epithelium of 
the distal esophagus is replaced by columnar epithelium (metaplasia) as a result 
of chronic esophageal reflux (1-4). Barrett's esophagus is associated with 
dysplasia and, compared to the general population, with a 30 to 40 fold increased 
incidence of esophageal adenocarcinoma (5,6). Patients with esophageal 
adenocarcinoma have a poor prognosis, even after surgical intervention. 
However, when surgical treatment is performed at an early stage, five year 
survival rates improve up to 100% (7,8). Surveillance of Barrett's esophagus 
patients is conducted by periodic endoscopy and histopathological examination of 
biopsy specimens. Although high grade dysplasia is considered an indication for 
surgical treatment (9-12), Barrett's esophagus with no or low grade dysplasia 
generally does not progress, but in individual cases is unpredictable. Therefore 
surveillance programs are unprofitable (13). Clearly, dysplasia cannot be the only 
criterium to recognize Barrett's esophagus patients with an increased risk for 
acquiring esophageal adenocarcinoma. To identify this subgroup prognostic 
parameters which can reliably predict malignant progression in Barrett's 
esophagus are required. 
Along with the development of neoplasia in Barrett's esophagus, cell cycle 
abnormalities and a broad spectrum of genetic events, ranging from point 
mutations to gross numerical and structural chromosomal rearrangements, have 
been observed (14-27). Increased proliferation rate in Barrett's esophagus were 
found ill PCNA and Ki-67 protein immunolabeling studies (14-16). Aberrations 
of the p53 gene have been found along with the development of neoplasia in 
Barrett's esophagus (17-20), as were aneuploidy and increased tetraploid cell 
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populations identified by flow cytometry (28-32). The most consistent numerical 
chromosomal aberration found in karyotyping studies is loss of the Y 
chromosome (21-24). By non-isotopic in situ hybridization (ISH), our group 
found V-loss in gastric (25), and esophageal adenocarcinomas (26). In the latter 
study, this aberration was also observed in Barrett's esophagus adjacent to 
adenocarcinoma. Recently, Hunter et al., using a similar ISH technique, found 
V-loss in 92 % of esophageal adenocarcinomas (27). 
Objective of the present study was to investigate ploidy, sex chromosome status 
and proliferation rate in non-dysplastic, dysplastic and neoplastic Barrett's 
esophagus. Ploidy and sex chromosome abnormalities were detennined by non-
isotopic in situ hybridization with (peri-) centromeric DNA probes specific for 
chromosomes I, X and Y. Ploidy in the esophageal adenocarcinomas was also 
measured by means of DNA flow cytometry. Accumulation of the Ki-67 antigen 
was assessed through immunohistochemistry. 
6.3 Materials and methods 
6.3.1 Tissue preparation 
Routinely formalin fixed paraffin-embedded tissues, obtained between 1987 and 
1993 from patients at our hospital, were used. The material consisted of 
endoscopic biopsies of 50 patients (32 male, 18 female) with Barrett's esophagus, 
23 esophagus-cardia resection specimens (16 male, 7 female) with 
adenocarcinoma in Barrett's esophagus and 4 lymph node metastases. All 
specimens were derived from different patients. In situ hybridization (ISH), 
immunohistochemistry (IHC) and flow cytometry were performed on consecutive 
tissue sections. For ISH and IHC, 4 I'm sections were cut from paraffin blocks 
containing tumor and/or Barrett's epithelium. Tissue sections were adhered to 
coated slides (!TK, Uithoom, The Netherlands) and stored overnight at 60°C. 
6.3.2 Histopathological criteria 
Hematoxylin and eosin stained sections from all tissue blocks were reviewed by 
two pathologists (A.H.M. and F.T.B.). Barrett's esophagus was defined as 
columnar epithelial lining of the esophagus at least three centimeters proximal to 
the gastro-esophageal junction. All cases had specialized colunmar type of 
metaplasia characterized by the presence of intestinal type of absorptive cells, 
e.g., goblet cells. Grading of dysplasia was performed following the criteria 
modified by Reid et al. (33), which distinguish three categories, i.e., no 
dysplasia, indefmite/low grade dysplasia and high grade. dysplasia. Eighteen 
biopsy specimens (11 male, 7 female) with Barrett's esophagus had no dysplasia, 
25 (16 male, 9 female) showed indefinite/low grade dysplasia, and seven (5 
male, 2 female) showed high grade dysplasia. Tumor staging was performed 
according to pTNM criteria. In nine (7 male, 2 female) of the adenocarcinomas 
infiltration was limited to the submucosa (pTl), in three (2 male, I female) to the 
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muscularis propria (pTI) and in 11 (7 male, 4 female) the serosa was invaded 
(pTI/4). Nine of the latter cases had lymph node metastases. 
6.3.3 Probe and probe labeling 
A probe set specific for chromosomes I, X and Y was selected. The (peri-) 
centromeric repetitive satellite DNA probes were labeled with biotin-14-dATP by 
nick translation of complete plasmid DNA according to manufacturer's directions 
(BRL, Gaithersburg, MD). DNA probes were stored at -20°C. 
Table 1 :Resu/ls of ill situ hybridlzatioll (ISH; with a set of chromosome specific repetitive DNA probes 
(1, X and Y). DNAjloll' C)'loll/elry alld imlllullollistodlemistry (IHC) with an amibody to Ki-67 oj 50 
biopsy specimells from Barrett's esophagus, 23 cases of adenocarcilloma in Barrett's esophagus. alld 
4 lymph node metastases. 
Cardia 
Normal 
ControP 
Total: 5 
Sex: 
Female 1 
Male 4 
me: 
PI>20%e 0 
ISH: 
Y lossf 0 
Hyperdiploid8 0 
Flow cytometry: 
Total: 
Anuploide/ tetraploidh 
II Normal cardta control IfsslIe. 
Barrett's esophagus 
Grade of dysplasia 
No ItL Highb 
18 25 7 
7 9 2 
11 16 5 
0 16 24 
1 6 5 
3 to 5 
Adenocarcinoma Metastasis 
Stage 
pT 1 pT2 pT3c LJu¥! ro;J,:,j 
9 3 
2 1 
7 2 
7 3 
6 2 
7 3 
9 2 
5 2 
11 
4 
7 
11 
6 
to 
to 
9 
4 
o 
4 
3 
4 
b Barrett's esophagus with 110 (No), illdefillifellow (IlL) alld high (High) grade dysplasia (34). 
( pT-Stages of esophageal adenocarcinoma according to pTNM classificatioll: pTJ.' TUmor ill 
submucosa, pT2: ill mliscularis propriae, pT3: ill advemitia. 
d LympJlIlode metastases of 4 male adellocarcinomas. 
e Proliferation index (PI), defilled as the percell/age of cells witli Ki-67 auagell expressioll (Mib-l 
immw/Ostaining). 
'The number of cases of Y chromosome-loss ill males. 
8 The lIumber of cases with ISH aI/euploidy defil/ed as > 4% hyperdiploid nuclei (> 2 ISH 
spots/nucleus) eS(;'lIated by ISH with a chromosome 1 specific ceil/TOll/eric DNA probe. 
h DNA flow cytometry of 21 adellocarcinomas: Vie number of carcinomas with aI/euploid peaks 
alld/or iI/creased G)Jltelraploidjraclioll. 
6.3.4 In Situ Hybridization 
The in situ hybridization procedure was performed as described earlier (26, 34), 
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with some slight modifications. Briefly, after deparaffinizing of the tissue 
sections in xylene, endogenous peroxidase activity was blocked with 0.3% H,O, 
in methanol. Prior to enzymatic digestion slides were heated in a microwave 
oven (Biorad, UK), submerged in 2XSSC at 85°C for 25 min with an interval of 
I min. During this interval fluid level was checked and restored. Further 
enhancement of tissue permeability was achieved by proteolytic enzyme digestion 
(pepsin: Sigma, I mg/ml in 0.2 M HCI) for 5-10 min at 37°C. Before applying 
the probe set, the optimal digestion time for each tumor was determined by a 
pepsin time series (5-10 min). Tissue DNA was heat denatured for 2 min in 70% 
formamide in 2xSSC (pH 7.0), followed by dehydration in an ethanol series. 
Chromosome specific repetitive DNA probes were denatured for 7 min at 70°C 
in a hybridization mixture, containing 1-2 I'g/ml probe DNA, 500 I'g/ml 
sonicated herring sperm DNA (Sigma), 0.1 % Tween-20, 10% dextran sulphate, 
and 60 % formamide in 2xSSC at pH 7. The probe mixture was then applied to 
the sections and incubated overnight at 37°C. Then slides were rinsed in 60% 
formamide in 2xSSC (pH 7.0) at 42°C. 
Histochemical detection of probe binding was performed by immunoperoxidase 
staining. Slides were incubated for 30 min at 37°C with mouse-ant i-biotin 
(DakopaUs, Glostrup, Derunark), biotin-labeled horse-anti-mouse (Vector, 
Burlingame, CAl and with avidin-biotin-complex (Vectastain Elite ABC Kit). 
Visualization was achieved with 0.05% H,O" 0.5 gil DAB, 0.1 M imidazole in 
PBS (Phosphate Buffered Saline). The signal was amplified with 0.5% CuS04 in 
0.9% NaCI. Slides were rinsed in distilled water and counterstained with 
hematoxylin. Finally, slides were dehydrated in ethanol, cleared in xylene and 
mounted in Malinol (Chroma-Geselschaft, Kongen, Germany). 
6.3.5 ImmunoWstochemistry 
Before immunolabeling enhancement of Ki-67 antigen staining was achieved by 
heating slides submerged in citrate buffer (10 mM citric acid monohydrate, pH 
6.0) in a microwave oven (700 W) at 95°C for 2x5 min with an interval of I 
min. During this interval fluid level was checked and restored. Labeling of the 
Ki-67 antigen was performed with a monoclonal antibody, Mib-I (Immunotech, 
Marseille, France), diluted 1/25 in PBS. The monoclonal Mib-I reacts with the 
Ki-67 molecule as detectable in late Gl, S and G2 phase, but not in GO phase of 
the cell cycle (35). For negative controls the primary antibodies were replaced by 
PBS. Immunohistochemistry was performed using the routine ABC-
immunoperoxidase method (Vector). 
6.3.6 DNA Flow Cytometry 
DNA content of the paraffin material of 21 carcinomas was measured, as 
described by Hedley et al. (36), using 50 I'm paraffin tissue sections. Flow 
cytometry was carried out using a Facscan (Becton Dickinson, Mountain View, 
Cal· 
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6.3.7 Analysis 
Results of ISH with probes for chromosomes I, X and Y were evaluated on 
consecutive 4 I'm sections in previously defined areas (26,34). This approach was 
applied to reduce artifacts due to biological heterogeneity and section thickness. 
Leukocytes on the same sections and stromal cells served as controls for 
hybridization quality. For each probe the number of solid DAB spots was scored 
(0, I, 2, 3, 4, >4 spots) of 2xlOO distinct, non-overlapping, single or side by 
side 4 I'm nuclear slices. Scoring was performed by two independent 
investigators. The counted spot distributions were compared and averaged. Loss 
of the Y chromosome appeared as small focal areas or extensive fields with 
absence of hybridization of chromosome Y in epithelial or cancer cell nuclei. 
Conversely, ISH spots had to be present in surrounding stromal cells and 
leukocytes. Aneuploidy (hyperdiploidy) was estimated by detennining the 
percentage of cells with more than 2 hybridization spots per nucleus afler ISH 
with the chromosome I specific (peri-) centromeric DNA probe. 
Figure. 1. Graphic represellfatioll of the results of ill situ hybridization with chromosome 1 and y, 
alld immllllohistochemistry with alld antibody for the KJ-67 amigell of: Barrett's esophagus wilh 110 
(N), indefinite/low (flL), high grade dysplasia (H) alld adenocarcinoma m. 'DIe Yaxis represellfs the 
percelltage oj cases with ele~'ated proliferation index (PI> 20), hyperdiploidy and chromosome Y-
loss, respecti~'e/y. Illcreased PI appears 10 be an early evellt during carcil/ogenesis ill Barrett's 
esophagus. Hyperdiploidy alld Y chromosome loss increase alollg with advancing dysplasia alld 
carcinoma. 
100-
80-
60-
40-
20-
o--~ 
N ,,1. H T 
D PI>20% Ill] Hyperdiploid • Y~loss 
Tissues were regarded hyperdiploid when > 4 % of the nuclei showed more than 
2 ISH spots. The sensitivity of this approach is high, since the detection of 
hyperdiploidy is not biased by G,M cells (34,37). In previous studies we have 
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also observed good correlations between ploidy as defined by ISH, and DNA 
flow cytometric measurements (26, 37). In control tissues, such as cardia, 
leukocytes and stromal cells, hyperdiploidy was < I %. 
Proliferation index (PI) was estimated by determining the percentage of Mib-l 
immunostained nuclei (2x200 cells; ref. 26). In Barrett's esophagus the 
percentage of positive cells was determined in longitudinally sectioned crypts and 
viii i. In the adenocarcinomas this was established by scoring of immunostained 
cancer cells. For control purposes PI was also determined in five cases of normal 
cardia tissue. The mean proliferative index (PI), in normal cardia specimens was 
15%. In Barrett's esophagus and adenocarcinomas a PI >20 was regarded as 
increased. 
6.3.8 Statistics 
The relation between dichotomous parameters was investigated using Fisher's 
exact test. The relation between the presence of a characteristic, i.e., 
hyperdiploidy or Y chromosome loss and histopathological grading was assessed 
using the Chi-square test for trend (38). Correlation coefficients given are 
Spearman's; p=0.05 (two sided) was considered the limit of significance. 
6.4 Results 
Proliferation rates were elevated (PI>20%) in all grades of dysplasia in Barrett's 
esophagus and in the adenocarcinomas (Table I; Figs. I, 2B, 3B). Furtherruore, 
mean PI gradually increased (r=0.65, p <0.001) along with increasing dysplasia 
in Barrett's esophagus from 40% to 51 %, reaching 63 % in adenocarcinomas. 
Ploidy as measured by DNA flow cytometry (FCM) correlated (p<0.05) with 
aneuploidy (hyperdiploidy) as found by ISH for chromosome 1. In 19 of 21 
adenocarcinomas both outcomes were concordant. The remaining 2 
adenocarcinomas were found diploid by FCM, whereas low percentages of 
hyperdiploid cells (range 5%-6%) were seen with ISH. 
Figure 2. Adjacel/t 4p.m tissue sectiolls of a biopsy specimen from a male patielll lVitlz Barrett's 
esophagus. A: Hemato.ryfill-Eosill stailled sectioll of Barrett's esophagus with specialized columnar 
type of metaplasia alld high grade dysplasia (2Ox obi). B: Immullohistochemical staillillg of the Ki-67 
allfigell with tile monoclollal antibody Mib-J ill Barrett's esophagus cOll1lterslailled with hematoxylin. 
(20x obj.). C: III sim hybridizarion (ISH) with a chromosome 1 specific DNA probe 011 a 4p.m fiSSile 
secfioll. TIle ISH-related spots were visualized with ;'l/IJl/l1loperoxidaseIDAB (black); hematoxylin was 
used as a counterstain (grey; IOOx obi). Note the presence oj liyperdiploid cells (arrows). D: ISH jor 
cliromosome Y shows focal loss in epithelial cells: A glalld with (0) al/d witholll (*) this chromosome 
can be distinguished. Also stromal cells comaill Y chromosome spots (4Ox obi). E: ISH with a 
chromosome X specific DNA probe shows clear hybridization for chromosome X ill the glalld Ihat 
showed loss oj Y ill D (4Ox obi). 
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Figure 2 
(A,B) 
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Figure 2 
(C) 
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Figure 2 
(D,E) 
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The percentage of cases with hyperdiploid cells gradually increased (p<O.OOI) 
from 17% in Barrett's esophagus biopsies without dysplasia, to 40% in cases 
with indefinite/low grade dysplasia, to 71 % with high grade 
dysplasia; 89% of carcinomas were found hyperdiploid (Table 1; Figs. 1, 2C, 
3C). The percentage of aberrant cells in the cases with hyperdiploidy ranged 
from 5% to 30%. The mean percentage of cells with abnormal ploidy increased 
(r=0.75, p<O.OOl) from 7% in cases with no/indefinite/low grade dysplasia to 
20% in Barrett's esophagus with high grade dysplasia or adenocarcinoma (Table 
I). 
Nine percent of Barrett's esophagus cases without dysplasia, 38% of cases with 
indefinite/low grade dysplasia, 100% of cases with high grade dysplasia and 88 % 
of the adenocarcinomas showed loss of the Y chromosome (p<O.OOI; Table 1; 
Fig. 1). Y chromosome loss in Barrett's esophagus was focal, but extensive or 
total in the adenocarcinomas (Figs. 2D, 3D). In three out of four lymph node 
metastases Y chromosome loss was found (Fig. 30). In the four lymph node 
metastases, Y 
chromosome status agreed with that of the primary adenocarcinoma. Numerical 
aberrations of the X chromosome were not found in any of the groups (Fig. 2E). 
In summary, a high proliferation rate was observed in all stages, whereas 
hyperdiploidy and Y-loss correlated with increasing degrees of dysplasia and 
carcinoma. Further, these parameters were not correlated within the different 
histopathological stages. In high grade dysplasia and adenocarcinomas prevalence 
of all 4 parameters was high, range 70-100% (Fig. 1). 
6.5 Discussion 
Optimal treatment of Barrett's esophagus patients requires early detection of 
malignancy. This has encouraged investigators to study biological parameters for 
use as prognostic markers. In this context we have investigated ploidy, numerical 
chromosomal abnormalities and proliferation rate in archival tissue sections of 
Barrett's esophagus patients with lesions ranging from simple intestinal type of 
metaplasia to metastasizing adenocarcinoma. We found that all these parameters 
were associated with progression of the lesions towards neoplasia. An elevated 
proliferation rate appeared to be an early change in Barrett's esophagus (Fig. I). 
Furthermore, the proliferation index gradually increased with advancing stages of 
development towards neoplasia. Although the latter observation was not always 
found by other investigators, proliferative activity is assumed to be elevated in 
both non-dysplastic and dysplastic intestinal type of Barrett's esophagus, and in 
esophageal" adenocarcinomas (14-16). 
Hyperdiploidy and Y chromosome loss appeared to increase with advancing 
degrees of dysplasia (Fig. 1). The percentage of hyperdiploid nuclei in no to low 
grade dysplasia was relatively low. In contrast to flow cytometry, non-isotopic in 
situ hybridization on tissue sections is highly efficient for the detection of (few) 
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Figure 3. Adjacem 4p.m tissue sectiolls of all esophageal adel/ocarcilloma alld lymph node metastasis. 
A: Hematoxylin-Eosin slailled sectiOll of moderately dijferellliated, esophageal adenocarcinoma (2Ox 
obj.). B: Immullohistochemical stail/illg of the Ki-67 am/gell with the mOl/oclol/al omibody Mib-l ill 
esophageal adenocarcinoma. (2Ox obj.). C: II/ situ hybridization (ISH) with a chromosome 1 specific 
DNA probe 011 a 4Jllll tissue sectioll, ISH shows mall)' hyperdiploid (> 2 spots) lIuclei (arrows; 40x 
obj.). D: ISH witll a chromosome Y specific DNA probe shows Y-Ioss ill carcilloma cells 
(arrowheads), bllt 1/01 ill stromal ,;ssue (arrows; 40x obj.). E: Same patient: Hematoxylin-Eosin 
stained 4p.m tissue sectiolls of a lymph node metastasis with leukocytes (*) and adenocarcinoma (0). 
F: ISH with a chromosome I specific DNA probe, re~'ealillg ISH signals ill both type of cells. G: ISH 
with a chromosome Y specific DNA probe shows Y-loss ill tumor nuclei (arrowheads), but not ill 
leukocytes (arrows). A 40;; objecti~'e was lIsed ill E-G. 
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dispersed cells with abnormal ploidy status (37). In the present study this was 
demol1Btrated by discordance of ploidy measured by FCM and ISH in two (of 21) 
tumor samples. Both samples were diploid by FCM, but were found to contain a 
low number of hyperdiploid nuclei by ISH. Y-Ioss was rarely observed in non-
dysplastic Barrett's esophagus, yet increased significantly in most advanced 
lesions with a high prevalence in high grade dysplasia and adenocarcinoma (Fig. 
I). Loss of the Y chromosome appears to be the most consistent chromosomal 
abnormality in Barrett's esophagus and esophageal adenocarcinoma. It was found 
previously in several karyotyping and ISH studies (21, 23-27). However, its 
association with dysplastic changes in Barrett's esophagus had not been observed 
previously. The role of Y-Ioss in neoplastic transfOlmation in Barrett's esophagus 
is uncertain. Barrett's esophagus and esophageal adenocarcinoma have a three 
and seven times increased incidence in males (39, 40). Since as yet no genes 
involved in tumorigenesis have been linked to the Y chromosome, Y-Ioss may be 
the result of genomic instability in transformed cells. In contrast to Y 
chromosome aberrations, X chromosome changes were not observed. The X 
chromosome is therefore not an informative numerical marker in (female) 
Barrett's esophagus patients. 
Our results suggest that during the development of dysplasia and carcinoma ill 
Barrett's esophagus a high cell turnover is an initial event. The resulting high 
proliferative activity may induce genomic instability. The latter leads to 
cytogenetic alterations, and transformation of cells, which may further expand 
into cell clones with malignant behavior. 
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7.1 Abstract 
TIle E-Cadherin-Catenin complex is important for cell-cell adhesion of epithelial 
cells. Impairment of one or more components of this complex is associated with 
poor differentiation and increased invasiveness of carcinomas. Esophageal 
adenocarcinomas cause early metastases, progress rapidly and consequently have 
a poor prognosis. By means of immunohistochemistry, we studied the expression 
of E-Cadherin, Alpha- and Beta-Catenin in 65 esophageal adenocarcinomas and 
15 lymph node metastases. Expression of these proteins was evaluated with 
respect to clinico-pathological parameters and patient survival. 
Expression of the proteins was strongly correlated. In carcinomas reduced 
expression of E-Cadherin, Alpha-Catenin and Beta-Catenin were found in 74 %, 
60%, and 72%, respectively. Expression of E-Cadherin and Alpha-Catenin 
correlated signit1cantly with stage and grade of the carcinomas, whereas 
expression of Beta-Catenin only correlated with grade of the carcinomas. 
Reduced expression of all three proteins correlated with shorter patient survival. 
In contrast to grade, E-Cadherin and Beta-Catenin were significant 
prognosticators for survival, independent of stage of disease. We conclude that in 
esophageal adenocarcinomas decreased expression of E-Cadherin, Alpha- and 
Beta-Catenin are related events. Furthermore, expression of at least E-Cadherin 
and Beta-Catenin, is significantly correlated with poor patients' prognosis. 
7.2 Introduction 
For several decades the incidence of esophageal adenocarcinoma in Western 
countries is rapidly increasing (1). The predisposing condition for developing 
esophageal adenocarcinoma is Barrett's esophagus (2-3). Progression of Barrett's 
esophagus to adenocarcinoma occurs through gradually increasing dysplasia (4-
5). The survival of patients with esophageal adenocarcinoma is poor, even after 
seemingly radical surgical intervention. Stage of disease is the best parameter for 
predicting survival (6, 7). Patients with limited tumor invasion of the esophageal 
wall and without metastases at time of resection have significantly better survival 
than those with lymph node metastases or organ infiltration (6, 7). Understanding 
the mechanisms of metastatic behavior of carcinomas, and recognition of cases 
running higher risk for developing metastases, might help to design new 
strategies for diagnosis and treatment. 
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E-Cadherin is a 120 KDa transmembrane glycoprotein, which belongs to a large 
family of calcium dependent adhesion molecules (CAMs) (8, 9). By mostly 
homotypic interactions (10), E-Cadherin plays an important role in 
morphogenesis of tissues during embryogenesis and in mature epithelia E-
Cadherin is involved in cell-cell adhesion (11, 12). In vitro and in vivo 
experiments showed that absence of membranous E-Cadherin in carcinoma cells 
goes along with increased invasiveness and metastatic ability (13-15). It has 
become clear that besides cellular adhesion, E-Cadherin is also involved in signal 
transduction via connections with Catenins and the actin cytoskeleton. The 
Catenin anchorage complex, which interacts with the cytoplasmic domain of E-
Cadherin, consists of a heteromere of at least three proteins: Alpha-, Beta- and 
Gamma-Catenin. Alpha-Catenin, a 102 kDa protein ubiquitously expressed in 
cells, binds to actin and to Beta-Catenin. In turn, Beta-Catenin, a 92 kDa protein, 
is directly linked to E-Cadherin (16, 17). Both Beta- and Alpha-Catenin have 
binding sites for several onco- and tumor suppressor proteins, suggesting that 
these might modulate the function of the E-Cadherin-Catenin adhesion complex 
(18-20). In adenocarcinomas of the prostate, breast, esophagus, lung, stomach 
and colon, and in squamous cell carcinomas of the esophagus and of head and 
neck, decreased E-Cadherin and/or Alpha-Catenin expression was found to 
correlate with high tumor grade and poor patients' prognosis (21-29). Recently, 
high frequencies of decreased Beta-Catenin expression were observed in several 
gastro-intestinal cancers (30). 
In the present report we describe the expression of E-Cadherin, (EC), Alpha-
(AC) and Beta-Catenin (BC) in 65 esophageal adenocarcinomas associated with 
Barrett's esophagus and in 15 lymph node metastases. Expression of these 
proteins, as assessed by immunohistochemistry with specific monoclonal 
antibodies, is evaluated with respect to various pathological parameters and 
patient survival. 
7.3 Materials and methods 
7.3.1 Clinico-pathological data 
Esophageal-cardia resection specimens of 65 patients with esophageal 
adenocarcinoma associated with Barrett's esophagus, encountered between 1985 
and 1992 at the Academic Hospital-Dijkzigt Rotterdam, were used in the study. 
Forty nine patients were male, 16 female, with a mean age of 67 (Range 34-80 
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years). All patients had undergone esophageal·cardia resection with 
microscopically complete removal of the carcinoma. Hematoxylin-eosin stained 
sections were used for tumor staging and grading. According to pTNM criteria, 
carcinomas were categorized into malignancies without (Stage 0, I, IIa) and with 
loco-regional or distant lymph node metastases (Stage lIb, III ). Carcinomas 
clearly showing glandular structures, with well developed intercellular junctions 
throughout the tumor, were classified as well/moderately differentiated 
carcinomas. Carcinomas were classified as poorly/undifferentiated when showing 
focally or diffusely solid growth without glands and with high cellular 
pleomorphism. Survival times were calculated from date of operation to death 
resulting from recurrence of disease, or to last clinical control date. 
7.3.2 Tissues 
Of each resection specimen one archival formalin fixed paraffin embedded tissue 
block, representing the deepest levels of tumor invasion into the esophageal wall, 
was selected for immunohistochemical study. In 15 cases lymph node metastases 
were included for immunohistochemical evaluation. Adjacent squamous cell 
epithelium or non·dysplastic columnar epithelium served as internal positive 
control for immunohistochemistry. 
7.3.3 Monoclonal antibodies 
For E-Cadherin staining we used the culture supernatant of a hybridoma clone, 
5H9, raised against a 80 kDa tryptic fragment of E-Cadherin from human A-431 
carcinoma cells (Organon Technika Boxtel The Netherlands) (31). Anti- Alpha-
Catenin IgGl monoclonal antibody (Affinity, Exeter UK) has been raised against 
Figure 1. Staillillg results of immullohistochemistry by tile (H'idill~biotin-peroxidase method, Di-
amilwbellZidill tetrachloride was used as a chromogen (black). AB: Normal expression as shown by 
homogeneous membrane stail/ing of the epithelial celfs (arrows) of Alpha-Carel/ill at the sqllamo-
colUmnar jUlIctioli (A), alld E-Cadllerill ill 1101l-dysplastic Barrett's esophagus (8). C: Homogeneous 
staining of all carcinoma ceU-membranes (arrows) indicatillg normal E-Cadllerill expression ill a well 
differemiated pT3 esophageal adenocarcinoma. D-F: Reduced expression with positive (arrows) and 
negative (arrowheads) cefts of: E-Cadherill in a poorly dijJerentiated pT3 adenocarcilloma (D), amI of 
Alpha- (E) and Beta- Catellill (F) ill a moderately dijJerellfiated esophageal adenocarcilloma. G: 
Normal expression, homogelleous membrane staillillg (arrows), of Alpha-Catellill expressioll ill a well 
dijJerellfiated adenocarcinoma. H: No membrane stainillg (arrowheads), but pos/ril'e nuclear staillillg 
(arrows) of Beta-Caten;1I ill a moderately dijJerellfiated adenocarcinoma. Magnification A: 9ar, B-H: 
18Q(. 
91 
Figure 1 
(A,B) 
92 
Figure 1 
(C.D) 
/ 
(I 
if} 
j 
93 
Figure 1 
(E,F) 
94 
Figure J 
(G,H) 
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a 19.4 kDa C-terminal protein fragment corresponding to amino acids 729-906 of 
mouse Alpha-Catenin. This antibody was diluted I: 100 ill PBS. A monoclonal 
IgGl Anti-Beta Catenin (Affinity), raised against 23 kDa protein fragment 
corresponding with amino acid residues 571-781 of mouse Beta-Catenin, was 
diluted 1 :200 in PBS. 
7.3.4 Immunohistochemistry 
Five I'm paraffin sections were mounted on 3-amino-propyl-tri-ethoxy-silane 
(Sigma, St. Louis, USA) coated slides and stored overnight at 60°C. Sections 
were deparaffinized, endogenous peroxidase was blocked in 3 % H,O, in methanol 
(20 min) and rinsed in PBS. As antigen retrieval procedure for E-Cadherin, 
tissues were digested in I % protease (Sigma) with 1 % Ca++ in PBS solution (10-
20 min at 37" C). Prior to Alpha- and Beta-Catenin staining the sections were 
heated in a microwave oven (in 0.01 M Citrate buffer Ph 6.0) for two cycles of 
five min. Primary antibodies were incubated overnight (at 4°C). As detection 
system we used streptavidin-biotin-peroxidase (Dako, Glostrnp Denmark) with 
diaminobenzidin tetrachloride (Fluka, Basel Switzerland) as chromogen. Tissues 
were counterstained with hematoxylin. 
7.3.5 Evaluation of E-Cadherin (EC), Alpha- (AC) and Beta-Catenin (BC) 
expression, 
Immunohistochemical staining of EC, AC and BC in the subsequent tissue 
sections was scored semi-quantitatively by two independent investigators in two 
areas per carcinoma and per lymph node metastasis(lOx objective). 
7.3.6 Statistical analysis 
Correlations between E-Cadherin, Alpha-, Beta- Catenin, grade and stage were 
calculated in cross-tables. Significance was tested by the Fisher's exact test. 
Survival probabilities were calculated by the Kaplan-Meier method and 
probabilities were compared by logrank test. Multi-variate analysis to determine 
independent prognostic value of the various parameters was performed by Cox 
regression. P=O.05 (two sided) was considered the limit of significance. 
7.4 Results 
7.4.1 IlIllllunohistochemical staining patterns in control tissues and in 
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adenocarcinomas. 
Homogeneous membranous immunostaining for E-Cadherin (EC), Alpha- (AC) 
and Beta-Catenin (BC) was found in all cases of normal squamous epithelium, 
normal cardia mucosa and non dysplastic Barrett's mucosa (figure IA,B). These 
tissues adjacent to the adenocarcinomas served as internal control for the staining 
procedures. In squamous epithelium immunostaining was present homogeneously 
Table 1: Cross tabulalioll oj immunohistochemical staining remits oj E-Cadherill, Alpha- and Beta-
Calellill lI'ith respect to stage and grade ill 65 esophageal adenocarcinomas, 
Pis E-Cadherin Alpha-Catenin Beta·Catenin 
normal reduced normal reduced normal reduced 
Total 65 17 48 28 37 18 47 
Stage": 
O,I,IIa (%) 33 15(88)' 18(38)' 21(75)' 12(32)' 12(67)' 21(45)' 
lIb,lII (%) 32 2(12) 30(63) 7(25) 25(68) 6(33) 26(55) 
Grade: 
Well/moder (%) 33 17(100)' 16(33)' 20(71)' 13(35)' 14(78)' 19(40)' 
Poor/undiff (%) 32 0(0) 32(67) 8(29) 24(65) 4(22) 28(60) 
E-Cadherin: 
normal (%) 17 17(61)' 0(0)' 11(61), 6(13)' 
reduced (%) 48 11(39) 37(100) 7(39) 41(85) 
Alpha-Catenin: 
normal (%) 28 16(89Y 12(25Y 
reduced (%) 37 2(11) 35(75) 
al Stages: O=pTisNOMO l=pT1NOMO; lla=pT213NOMO; llb=pT1I2N1MO; 11l=pT314Nl-3MO 
Column percellfages. Np < 0.001 clp =O.OOl dJp =0.17 tip < 0.001 /.~Ip <0.01 h-j!p < 0.001 
on the intermediate cells and on the basal layer (but not at the basal membrane 
side). In non dysplastic Barrett's and cardia epithelia intercellular membrane 
staining was seen between all columnar cells. 
Membrane staining for all three proteins was also found in the adenocarcinomas 
and lymph node metastases. In the adenocarcinomas and lymph node metastases 
three main staining patterns were recognized: Homogeneous positive staining 
with more than 90% positive cells (figure IC,G). Heterogeneously staining 
carcinomas with mixed negative and positive cells or tumor areas (figure 
ID,E,F), but with at least 30% negatively staining cells. And a group of 
carcinomas with negative staining with no or less than 10% positive cells (figure 
IH). For further analysis, carcinomas displaying a homogeneous positive pattern 
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were regarded as staining normally, whereas the latter two patterns, 
heterogeneous and negative were taken together and classified as reduced 
staining. Occasionally, in carcinomas with reduced AC or BC staining, weak to 
intense cytoplasmic staining for both proteins and for BC also nuclear staining 
was observed (figure lH). 
Table 2; Esophageal adellocarcinoma specific five years survival probabilities, 
subsequemly stratified for stage, grade, and immul/oreactive E-Cadherill, 
Alpha-alld Beta-Catel/in expressiol/. 
patients 5-yrsl) SDl) p-value11 
Overall 65 32% 0.07 
Stage4): 
D,I,ITa 33 64% 0.10 
IIb,llI 32 7% 0.10 0.0001 
Grade of differentiation: 
Well/moderately 33 55% 0.10 
Poor/undifferentiated 32 10% 0.10 0.0001 
E-Cadherin expression: 
E-Cadherin normal 17 74% 0.12 
E-Cadherin aberrant 43 14% 0.7 0.001 
Alpha-Catenin expression: 
Alpha-Catenin normal 28 61 % 0.10 
Alpha-CateoiD aberrant 37 11% 0.06 0.001 
Bcta-Catenill expression: 
Bela-Catenill normal 18 64% 0.14 
Beta-Cateoin aberrant 42 21 % 0,07 0.01 
IJKapiall-Meier'sjil'e year sun'ivai probability. ])StalJdard del'latioll. 3)p-value 
calculated by Logrank test. 
f)Srages: 0= TisNOMO; l=pTINOMO; lla=pTlI3NOMO; lib=pT1I2NIMO; 
Ill~pT3I4Nl-3MO. 
7.4.2 E-Cadherin (EC), Alpha- (AC) and Beta-Catenin (BC) expression in 
esophageal adenocarcinoma, 
Of the 65 esophageal adenocarcinomas 33 (51 %) were classified as 
well/moderately differentiated and 32 (49%) as poorly/undifferentiated. Thirty-
three (51 %) of the carcinomas had no metastases (stage O,I,lIa), but 32 (49%) 
had loco-regional or distant lymph node metastases (stage lib, III ; table 1). 
Reduced EC, AC and BC imrnunostaining was found in 48 (74%), 37 (60%) and 
47 (72%) of the cases, respectively (table 1). 
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AC immunostaining correlated significantly with BC stammg. EC 
immunostaining correlated significantly with both AC and BC (p-values <0.01, 
Fisher's exact test; table I). Staining of all three proteins was reduced in 
35(54%) cases. Forty-three (66%) of the cases showed reduced staining of at 
least two, 54 (83%) of at least one of the proteins. 
Reduced inununostaining in poorly and undifferentiated carcinomas of EC, AC 
and BC was found in 67, 65, and 60% versus 33, 35, 40% in the well and 
moderately differentiated cases, resp. Staining of EC, AC and BC correlated 
significantly with tumor grade (p-values <0.01, Fisher's exact test; table I). 
In carcinomas with metastases reduced EC, AC and BC staining was seen in 63, 
68, and 55% versus 38, 32 and 45% in carcinomas without metastases, 
respectively. Immunostaining of only EC and AC correlated significantly stage of 
disease (p-values <0.01, Fisher's exact test; table I). 
Median follow-up period of patients was 23 months (Range 3-114 months). 
Overall five year survival was 32 %. Significant differences in survival were 
found when patients were grouped according to stage (stage 0, I, I1a versus lIb, 
Ill), grade (well/moderate versus poor/undifferentiated), and for EC, AC and BC 
(normal versus reduced staining), (p-values <0.05, logrank; table 2; figure 2). 
Upon multi-variate analysis, in addition to stage, no significant prognostic value 
remained for grade (p=0.15). Adjusted for stage, BC was still an important 
prognostic factor (reduced versus normal: relative death rate=2.67; p=0.03). 
The same applied to EC (relative death rate=2.72, p=0.04), but not to AC 
(p=0.09). Figures 2C and 2D show the effect of norrual and reduced BC staining 
within the groups of patients without metastases(stage 0, I, na; figure 2C), and 
with metastases (stage lIb, 1II; figure 2D). Due to strong correlation between 
EC, AC and BC expression, data did not allow to define which of these 
parameters might be superior to the other in predicting survival. 
Figure 2. A-D: Kaplan Meier slln'imi curves. X-axis: Survival ill mom"s; Y-axis: % oj patiellts. 17le 
interrupted Iille in A alld B shows jive years surviml of tile whole group,' ill C alld D of stage O,l,Jla 
and stage /lb,lIl, respectb'ely. A,B: Sigllijicallt differences of survival probabilities for patiems wilh 
esophageal adenocarcinomas are shown, as subsequently stratified for reduced verslls I/ormal 
expressioll of E-Cadherifl(EC) and Bela-Gaten/" (BC) (Lograllk lest p < 0.05). C; Further stratification 
within the group of patiellts without metastases (stage 0, I, lIa), fol/owillg reduced and normal 
expressioll of Beta-Catell/n, illustrates a significallt difference ill survival betweell patiellfs wilhout 
metastases and 1I0rmai BC expressioll, alld without metastases but reduced BC expressioll (lograllk 
test p,O.OS). D: Further stratification following BC expressioll within the group of patiellls with 
metastases, shows 110 sigllijicalU difference beMeell the two groups. Notice that ollly 6 out of 32 
patiellls witl/metastases have reduced BC expression, 
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7.4.3 E-Cadherin (EC), Alpha- (AC) and Beta-Catenin (BC) expression in 
lymph node metastasis. 
In the 15 investigated lymph node metastases, heterogeneous or homogeneous 
positive membrane staining for EC and BC was found in 14 (93 %) and for AC in 
13 (86%) cases. All these lymph node metastases corresponded with 
heterogeneously or normally expressed EC, AC and BC in the primary cancers. 
All but one of the negatively staining (less than 10% positive cells) lymph node 
metastases arose from heterogeneously stained primary carcinomas. One 
metastasis, which was negative for AC corresponded with a normally AC 
expressing carcinoma. 
7.5 Discussion 
The E-Cadherin-Catenin complex is part of a larger system, including in addition 
to Alpha- and Beta-, also Garnma-Catenin (plakoglobin), which is linked to the 
actin cytoskeleton (16, 17, 32). As E-Cadherin (EC) is responsible for tight 
cellular connections, expression of EC between epithelial cells is concentrated at 
tight junctions, adherens junctions and desmosomal regions (33). The Catenins, 
which connect EC with the actin cytoskeleton, are essential for EC function since 
deletion of the intracellular Catenin binding domain of EC results in loss of 
adhesive function, even when the extracellular portion of EC is intact (16, 17, 
34-35). In carcinomas several mechanisms may impair the function of the E-
Cadherin-Catenin complex, which might result in increased invasiveness and 
metastatic ability of malignant cells. Gene mutations or deletions and decreased 
expression, and transcriptional and translational abnormalities have been found 
for EC and Alpha-Catenin (AC) in several malignancies (36-38). Alternatively, 
down-regulation of the protein complex appears to occur through phosphorylation 
or competitive binding of Beta-Catenin (BC) to tumor suppressor proteins, such 
as APC, oncoproteins for instance C-erbB-2, and growth factors such as EGF-R 
(18-20, 39-42). Consequently, overexpression of such onco proteins and growth 
factors or mutated APC in carcinomas may influence tumor behavior through 
modulation or down regulation of the E-Cadherin-Catenin complex (43-45). In 
esophageal adenocarcinomas overexpression of EGF-R and C-erbB-2 have been 
frequently found. In several studies C-erbB-2 has been correlated with poor 
patients' prognosis (43-45). Frequent 5q (APC) allelic loss has been documented 
in esophageal adenocarcinomas (46-48). However, in these malignancies APC 
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gene mutations appears to be rare (49). 
In various gastro-intestinal cancers a high percentage of tumors with reduced EC, 
AC and BC expression have been observed. This phenomenon generally appears 
to be correlated with poor differentiation grade or increased tumor stage (24-28). 
In squamous cell carcinoma of the esophagus and colon carcinoma, reduced EC, 
AC and BC expression has been found in 70%-80% of cases (25, 26, 28, 30). In 
gastric cancers reduced EC, AC and BC expression has been observed in 55 % 
(33/60),70% (42/60) and 47% (9/19) of the cases, respectively (25,27,30). E-
Cadherin gene mutations were discovered in 50% of diftiIse type gastric 
carcinomas(36). In scirrhous gastric adenocarcinomas, however, the frequency 
(55 %) of reduced AC expression was much higher than that of reduced EC 
expression (18%)(50). 
Recently Bongiorno et al., showed reduced expression of E-Cadherin in 86% 
(37/43) of esophageal adenocarcinomas, correlating with stage of disease. 
However, positive EC staining was observed in 100% (12112) of the lymph node 
metastases(24). In esophageal adenocarcinomas, to our knowledge, no literature 
data is available concerning AC and BC expression in esophageal 
adenocarcinomas. In the present study we observed reduced BC expression as 
frequently as reduced EC and slightly more frequently than reduced AC 
expression in esophageal adenocarcinomas. EC and AC, but not BC were 
significantly correlated with stage of disease (Table 1). Nevertheless, BC status 
correlated significantly with survival, independent of stage of disease. 
At the level, immunohistochemical findings were compared with clinico-
pathological data. Reduced EC, AC and BC expression was found in between 60 
and 75% of cases. Moreover, expression of the three proteins was strongly 
correlated. Reduced expression of EC and AC correlated with unfavorable 
clinico-pathological parameters, such as poor differentiation grade, advanced 
stage and poor survival. Interestingly, reduced BC expression did not correlate 
with stage of disease but strongly correlated with poor differentiation grade and 
shorter survival. In our study almost all (90%) lymph node metastases expressed 
all three proteins. The slightly higher number of cases with altered EC staining 
observed by Bongiorno et al., as compared to the present results, may be 
explained by methodological differences and the higher number of advanced stage 
carcinomas in their study (24). The unexpected observation of homogeneous 
positive expression of the proteins in lymph node metastases, even from 
carcinomas with reduced expression, may be explained by transient down 
regulation of the protein complex in cancer cells followed by (re)expression of 
103 
the complex in metastasized cells, re-establishing tissue architecture, which 
requires cell adhesion. Future investigations on the regulation of the expression 
of these proteins may elucidate this enigma. 
In conclusion EC, AC and BC expression in esophageal adenocarcinomas are 
significantly correlated. Reduced expression of EC, AC and BC is correlated 
with less favorable clinico-pathologicaI parameters. Moreover, EC and BC 
expression are prognostic parameters, independent of stage, which might be used 
to identify patients which run a higher risk for developing disease recurrence. 
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Chapter 8 
CD44st and CD44v6 Splice Variant Expression in Barrett's 
Esophagus and Barrett's Adenocarcinoma. 
K. K. Krishnadath, H.W. Tilanus, M. van Blankenstein, 
W.C.J. Hop, E. Kremers and F.T. Bosman. 
Submitted to Am J Surg Patho] (April 1997) 

8.1 Abstract 
CD44 is a family of glycoproteins involved in cell-cell and cell-matrix 
interactions. The standard CD44 form (CD44st) of only 90 kDa is present on 
most hematopoietic and various epithelial cell types. Larger CD44 forms between 
140-230 kDa exist as alternatively spliced exons are inserted in the extracellular 
domain of the CD44 protein. Expression of CD44 with insertion of the variable 
exon 6 product (CD44v6) in several malignancies is associated with increased 
metastatic potential. To analyze the role of CD44 in adenocarcinoma of the 
esophagus, we studied expression of CD44st and CD44v6 in 35 cases of Barrett's 
esophagus, in 70 resected esophageal (Barrett'S) adenocarcinomas and in 22 
lymph node metastases by immunohistochemistry. Expression of CD44st and 
CD44v6 in Barrett's esophagus was compared with grade of dysplasia and Ki-67 
defined proliferation rate. In the adenocarcinomas expression of CD44st and 
CD44v6 was evaluated with respect to clinico-pathological parameters. In 
Barrett's esophagus, CD44st expression increased along with the rate of 
proliferation and dysplasia (p <0.01). In contrast, increased CD44v6 expression 
was seen in an early stage of malignant transformation. In esophageal 
adenocarcinomas, increased CD44st and CD44v6 expression was observed in 
50% (35170) and 83% (58170), respectively. No significant correlations were 
found between expression of CD44st and CD44v6 and grade or stage of the 
carcinomas. A trend towards improved five years survival was found for the 
group without increased CD44v6 (24% versus 55%; p=0.06). In the lymph node 
metastases CD44st and CD44v6 were positive in 45% (10122) and 64% (14122) 
cases. In conclusion, in Barrett's esophagus CD44st expression increases along 
with dysplasia and the proliferation rate. Increased CD44v6 occurs early during 
malignant transformation. Furthermore, esophageal adenocarcinoma patients with 
increased CD44v6 expression tend to have poorer five years survival. 
8.2 Introdnction 
Barrett's esophagus is a disorder predisposing for esophageal adenocarcinoma. 
Progression of Barrett's esophagus to adenocarcinoma occurs through gradually 
increasing dysplasia, along with increased proliferation and accumulation of 
genetic changes (1-9). Only a fraction of Barrett's esophagus will progress into 
esophageal adenocarcinoma (10-13). Once this invasive malignancy occurs, 
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survival of patients is poor, even after seemingly radical surgical intervention 
(14, 15). Therefore, it is important to lInd emcient screening paranleters, which 
can identify Barrett's esophagus patients at high risk for malignant 
transformation. An additional problem is the rapidly increasing incidence of 
esophageal adenocarcinomas. Since the vast majority of Barrett's esophagus 
patients have little or no symptoms and therefore is not surveyed, most of the 
malignant cases are detected when dysphagia and weight loss occur and disease is 
advanced. Despite surgical intervention, overall five years survival of patients 
with esophageal adenocarcinoma is poor. The presence of metastases is one of 
the most important factors detennining the prognosis of the patient (14, 15). 
Little biological data is available concerning progression and metastatic behavior 
of esophageal adenocarcinomas. Understanding these mechanisms and identifying 
factors involved in these processes are of major concern and could improve 
treatment protocols. 
The CD44 protein is a multi functional cell surface molecule, involved in 
processes as lymphocyte homing, lymphocyte activation and extracellular matrix 
and intercellular adhesion (16). As a result of alternative splicing of 10 exons 
(vl-vlO) more than 20 isoforms have been described. The standard hemopoietic 
variant (CD44st), sized 90kD, lacks all 10 variable variants and is expressed on a 
variety of tissues such as epithelium, fibroblasts and cells of hematopoietic origin 
(17). Gunthert et. al. (18), detected the association between the expression of 
certain CD44 splice variants and metastatic behavior of cells. Transfection 
experiments proved that naturally non-metastasizing cells, when transfected with 
the CD44-v6 splice variant, were transformed into metastatic cells (19). Although 
the role of CD44 splice variants is not completely understood, the presence of 
certain splice variants were shown to correlate with metastatic behavior of several 
cancers, including gastrointestinal malignancies (20-24). In most malignancies the 
CD44-v6 splice variant is overexpressed and then associated with unfavorable 
clinico-pathological features. Alternatively, tissue specific overexpression of 
splice variants has been documented. For instance, upregulation has been found 
in cervical carcinoma of CD44v7-8, in diffuse type gastric carcinomas of 
CD44v5, in gastric and renal carcinoma of CD44v9-1O (20, 22, 25, 26). In colon 
carcinomas expression of CD44v8-1O has been associated with hematogenous 
metastases, while in general alternatively spliced variants correlate with poor 
prognosis (27, 28). Interestingly, in colon adenomas CD44v6 expression is 
correlated with dysplastic features (29-31). 
In the present study we evaluated, by immunohistochemistry, CD44st and 
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CD44v6 expression in archival material of 35 cases of Barrett's esophagus, 70 of 
Barrett's adenocarcinomas and 22 lymph node metastases of the esophageal 
adenocarcinomas. In Barrett's esophagus CD44 immunostaining results were 
compared with dysplasia and proliferation rate as reflected in Ki-67 expression. 
In adenocarcinomas staining results were evaluated with respect to 
histopathological parameters and patient survival. 
8.3 Material and Methods 
8.3.1 Clinico-pathological data 
Barrett's oesophagus was defined as colunlllar epithelial lining of the oesophagus 
at least three em proximal to the gastroesophageal junction. Only cases with 
specialized columnar type of metaplasia, characterized by the presence of 
intestinal columnar cells and goblet cells, were included. Dysplasia was graded 
into three categories following criteria revised by Reid et al, i.e.; negative, 
indefinite or low grade dysplasia, and high grade dysplasia (32). TIlirty five cases 
of Barrett's esophagus, encountered between 1987 and 1992 at the Academic 
Hospital-Dijkzigt Rotterdam, were included for immunohistochemical study, 26 
(74%) male and 9 (26%) female. Mean age was 62 (range 28 to 81). Thirty two 
cases of Barrett's esophagus were biopsy specimens of patients without 
esophageal adenocarcinoma; three Barrett's esophagus were esophageal resection 
specimens with high grade dysplasia but without invasive carcinoma. 
Seventy cases of resected esophageal adenocarcinomas associated with Barrett's 
oesophagus, encountered between 1985 and 1992, were included in this study. In 
addition in 22 cases lymph node metastases were investigated as well. Fifty three 
of these patients were male, 17 female, mean age was 67 (Range 34-80 years). 
All patients had undergone cardia-esophageal resection with microscopically 
complete removal of the carcinoma. Hematoxylin-eosin stained sections were 
used for tumor staging and grading. According to pTNM criteria, carcinomas 
were categorized in malignancies without (Stage I, lIa) or with loco-regional or 
distant lymph node metastasis (Stage lIb, III). Carcinomas which clearly showed 
glandular structures, with well developed intercellular junctions throughout the 
tumor, were classified as well/moderately differentiated carcinomas. Carcinomas 
were classified as poorly/undifferentiated when focally or completely 
characterized by lack of differentiation and high nuclear pleomorphism. Survival 
times were calculated from the date of operation to death resulting from 
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recurrence of disease, or to last clinical control date. 
8.3.2 Tissnes 
Of each resection specimen the formalin fixed paraffin embedded tissue block 
representing deepest level of tumor invasion in the esophageal wall, and in 22 
cases also one paraffin block with lymph node metastases was selected for 
immunohistochemical investigations. Of the Barrett's biopsy specimens, per case 
only those biopsies representing the highest degree of dysplasia were used for 
immunohistochemical evaluation. Adjacent squamous cell epithelium or non 
dysplastic columnar (cardia) epithelium served as internal positive control. 
8.3.3 Monoclonal antibodies 
Monoclonal IgGl antibodies, Mab VFF-18 (diluted 1: 100 in PBS), which 
specifically recognizes the epitope encoded by exon v6 of the variant portion, and 
Mab SFF-2 (diluted 1:100 in PBS), which reacts with an epitope of the non-
variable portion of the human CD44 molecule were used for CD44v6 and 
CD44st staining respectively (Bender Med Systems, Vienna Austria). The Mib-I 
IgG monoclonal antibody (diluted I :50 in PBS) which specifically recognizes the 
Ki-67 antigen expressed in cycling cells, was used to determine proliferation in 
Barrett's esophagus (Dako, Glostrup Denmark). 
8.3.4 Immunohistochemistry 
Five !"m paraffin sections were mounted to 3-arnino-propyl-triethoxy-silane 
(Sigma, St. Louis, USA) coated slides and stored overnight at 60'C. Sections 
were deparaffmized, endogenous peroxidase was blocked in 3 % H,O, in methanol 
for 20 minutes and rinsed in phosphate buffered saline (PBS). For enhancement 
of Ki-67, CD44st and CD44V6 staining, the sections were heated in a microwave 
oven (submerged in 0.01 M Citrate buffer pH 6.0) for two cycles of five 
minutes. Appropriately diluted monoclonal antibodies were applied to sections 
and left for overnight incubation at 4'C. As a detection system we used 
streptavidin-biotin-peroxidase (Dako, Glostrup Denmark) with diarninobenzidin 
tetrachloride (Fluka, Basel Swiss) as chromogen. Tissues were counterstained 
with hematoxylin. 
8.3.5 Evaluation of proliferation (Ki·67 autigen staining), CD44st, and 
CD44v6 expression in Barrett's esophagus 
In Barrett's esophagus, Ki-67 staining and staining of CD44st fUld CD44v6 were 
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scored by two independent investigators. Three increasing levels of expression 
were defined in Barrett's esophagus. Compartment I (Cl) was defined as the 
glandular or crypt portion of the mucosa; compartment 2 (C2) included staining 
in the neck area of the villus; compartment 3 (C3) also included the luminal side 
of the villus (fig. IB). 
8.3.6 Evaluation of CD44st and CD44v6 expression in esophageal 
adenocarcinomas and lymph node metastases 
ltillnunohistochemical staining of CD44st and CD44v6 in subsequent tissue 
sections was scored semi-quantitatively, in 10% intervals (0-10%, 10-20%, etc) 
by two independent investigators in three previously selected areas per carcinoma 
(lOx objective). Percentages as scored by the two investigators were averaged per 
tumor area. In order to compare inmmnohistochemical results with 
clinicopathological data, eventually one average score per carcinoma was 
calculated. Since CD44st and CD44v6 are normally expressed in the crypt zone 
of non dysplastic intestinal type (metaplastic) epithelium, carcinomas were 
considered as having increased CD44st or CD44v6 expression when on average 
more than 20% of cells was positive. 
8.3.7 Statistical analysis 
In Barrett's esophagus differences in expression of CD44st, CD44v6 and Ki-67 
expression were calculated by Wilcoxon signed rank test. Correlations between 
these parameters and dysplasia in Barrett's esophagus, and the correlation 
between the CD44st and CD44v6 in adenocarcinomas were evaluated by 
calculating Spearman's rank correlation coefficient. 
Figure 1. A (a, (3, i): immunohistochemical stainillg (lHe) showillg nuclear staillillg of Ki~67 (a), 
alld membranolls stail/ing of CD44st ({3) alld CD44v6 ("I) ill normal stratified squall/oils epithelium of 
the esophagus (arrows). Stainillg of the fhree epitopes is fOlllld ill the same area of the epithelium. 
Nolice 'hat staining of CD44\'6 is more illfellse Ihall of CD44st. B-D: subsequellf sections Of a 
Barrett's esophagus wit" loll' grade dysplasia, stained/or Ki-67, CD44st alld CD44~'6 respect/l'e/y. B: 
The defined areas for scoring IHC results are shown: Compartmellts Cl: glalld and crypt zone; C2: 
CI + /leck zone and C3: C2+ luminal side. Ki-67 positive are showll ill C2 (arrow heads). C, D: 
CD44st and CD44~'6 positb'e cells are foulld ill C3 (arrows). Notice that virtually all epithelial cells 
are stailled for CD44~'6. E, F: Subseqltellt sec/iolls of a moderately differentiated esophageal 
adenocarcinoma stailled for CD44s/ and CD44v6, respectj~'ely. E: Most carcilJoma cells lack CD44st 
stainillg (arrows), whereas stromal cells and leukocytes sholl' positive membrane stainillg (arrow 
heads). F: CD44l'6 stailling is presellt 011 almost alt carcinoma cells (arrows), whereas stromal cells 
are lJegative (arrow heads). 
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(A) 
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Figure 1 
IB,C.D) 
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Figure 1 
IE,F) 
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Cross tabulations were perfonued to assess correlations between CD44st and 
CD44-V6 expression, and grade and stage of the carcinomas. Significance was 
tested by the Fisher's exact test (two tailed). Survival probabilities were 
calculated and compared by the Kaplan-Meier method and logrank test. 
Multivariate analysis to determine independent prognostic value of the various 
parameters was perfonued by Cox regression. For all tests, p=O.05 (two sided) 
was considered the limit of significance. 
8.4 Results 
8.4.1 CD44st and CD44v6 in control tissues, Barrett's esophagus and 
esophageal adenocarcinomas 
Homogeneous membrane immunostaining for CD44st and CD44v6 was found in 
all cases of normal squamous epithelium and in the crypts and glands of normal 
cardia mucosa and non dysplastic Barrett's epithelium (figure lA, B). These 
tissues adjacent to the adenocarcinomas served as internal controls for the 
staining procedures. In squamous epithelium membrane immunostaining was 
present homogeneously on the intenuediate cells and on the basal layer, but not 
on the basal membrane side of the basal cells (figure lA). In columnar cardia 
epithelium, intercellular membrane staining was only seen in the gland and crypt 
zone. In both squamous epithelium and columnar epithelium CD44v6 staining 
was more often found and more intense than CD44st (figure lA). Membrane 
staining for CD44st, but not for CD44v6, was seen for a variety of other 
different cell types, including lymphocytes and stromal cells. 
8.4.2 Dysplasia, Ki-67 antigen (proliferation), CD44st and CD44v6 in 
Barrett's esophagus 
Thirty five cases of Barrett's esophagus were analyzed for dysplasia, Ki-67 
antigen expression, and CD44st and CD44v6 immunoreactivity (figures lB-D). 
Fourteen cases were non dysplastic, 16 showed indefinite or low grade dysplasia 
and five cases were highly dysplastic (figure 2). 
In Barrett's esophagus without dysplasia proliferation was observed in Cl in 
13/14 and in C2 in 1114. In all non dysplastic cases CD44st was seen in Cl only. 
In contrast, CD44v6 was seen in Cl, C2 and C3 in 8/14, 5/14 and 1114 Barrett's 
esophagus without dysplasia. 
In cases indefinite for dysplasia or with low grade dysplasia, Ki-67 antigen was 
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observed in CI, C2 and C3 in 6/16, 8116 and 2116; CD44st in 9/16, 6116 and 
1/16; and CD44v6 in 3116, 4/16 and 9116 cases, respectively (figures IB-D, 2). 
In Barrett's esophagus with high grade dysplasia Ki-67 antigen staining was 
positive in C2 and C3 in 2/5 and 3/5; CD44st in 1/5 and 4/5 cases, respectively. 
In all five cases of high grade dysplasia CD44v6 staining was seen in C3. 
Both Ki-67 and CD44st staining correlated significantly with grade of dysplasia 
(table 1; Spearman rank corr coef. 0.7, p<O.OOl). Overall, CD44v6 staining, 
compared to CD44st and Ki-67 expression, was significantly more frequently 
observed in C2 and C3 (figure 2; table I, Wilcoxon signed rank test p <0.01). 
CD44v6 expression did not correlate with dysplasia. 
NO DYSPLASrA LOW/lNDEFlN1TE llGHGRADE 
100 
% 
p Y$I ... p 
• C3 E3 C2 0 Cl 
Figure 2: Y-axis: Percelllages of patiellfs willi Barrell's esophagus without dysplasia, witll 
indefinite/low grade dysplasia alld with high grade dysplasia, respectively. X-aris: P: proliferative 
activity assessed by Ki-67 antigell immunohistochemistry (IHC). sf: CD44s1 expression. v6: CD44v6 
expressioll. Cl.' immunohistocliemical sln/lIgillg ill gland alld crypt ZOlle of villi; C2: ill Cl alld neck 
zone,' C3: ill C2 and lumillal side oj villi. Notice that Ki-67 alld CD44st inmlllllos/oilling ill C2 alld 
C3 OCCllrs as dysplasia iI/creases. CD44~'6 immflllosfaillg ill C2 and C3 is seen ill all cases of high 
grade dysplasia but as well ill 77% of cases with indefinite/lolV grade dysplasia alld 43% of cases 
without dysplasia. 
8.4.3 CD44st and CD44v6 ill esophageal adenocarcinomas 
Of the 70 esophageal adenocarcinomas 37 (53 %) were classified as 
well/moderately differentiated and 33 (47%) as poorly/undifferentiated. Fifty 
percent of the carcinomas had no (stage 0, I, lIa), the other 50% had loco-
regional or distant lymph node metastases (stage lIb, III ; table 2). 
In the adenocarcinomas, a median score of 21 % (S.D. 26) for CD44st positive 
cells was calculated. For CD44v6 expression a median score of 58% (S.D. 27) 
was calculated. There was no correlation between CD44st and CD44v6 
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Table 1: Cross tabulation of immltlfoliistocliemical staining results witli monoclonal antibodies against 
the CD44st and CD44v6 epitopes i1l 70 esopliageal adenocarcinomas. 
PIs CD44st CD44v6 S·yrs 
normal increased p" normal increased p" p" 
Total (%) 70 35(50) 35(50) 12(17) 58(83) 
Stage3): 
O,I,lIa (%)4) 35 15(43) 20(57) 8(67) 27(47) 45%-S) 
IIb,lll 35 20(57) 15(43) 0.17 4(33) 31(53) 0.17 0% <0.001 
Grade6>: 
weWmodcr 37 21(60) 16(46) 11(92) 26(45) 35% 
poor/undiff 33 14(40) 19(54) n.s. 1(8) 32(55) <0.01 12% <0.01 
CD44st 
normal 35 9(75) 26(45) 37% 
increased 35 3(25) 32(55) n.s. 25% n.s. 
CD44v6 
normal 12 55% 
increased 58 24% 0.06 
1) p-value by two tailed Fisher exact test. 2) p-mlue by /ogrank test. 3) Stage: O=pTisNOMO 
l=pTlNOMO lla=pT2-3NOMO; llb=pT12NIMO IlI=pT3-4Nl-3MO. 4) (%) column percel/lages. 5) 
Five years sltrvi\'ai probability calculated by Kaplan-Meier method. 6)Grade: WelllModerately; 
poorly-tIIldifferentiated. 
Immunostaining. Increased CD44st and CD44v6 expression (>20% positive 
cells) was seen in 49% (34170) and 83% (58170), respectively (figure I, table 2). 
Overall survival correlated significantly with stage and grade of disease. Overall 
five years survival of patients without metastases at time of resection was 45 % 
compared to 6% for patients with metastases at time of resection (logrank test 
p<O.OOI). For patients with well and moderately differentiated adenocarcinomas 
five year survival was 35% compared to 12% for those with poorly or 
undifferentiated adenocarcinomas (logrank test p<O.OI). Survival of patients 
with normal or increased expression of CD44st did not differ. A trend was found 
for the group with increased CD44v6 to shorter survival (55 % . versus 24 %; 
10grank test p =0.06; figure 3). 
Upon multi-variate analysis stage was the only prognostic factor, which, 
independently of grade, CD44st and CD44v6 expression, predicted survival (Cox 
regression analysis p<O.OI). 
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Figure 3: Kaplall Meier survival curves showillg five year survival of patients with esophageal 
adenocarcinomas wilh normal (11=12) verslls increased (11=58) CD44v6 expressioll. A trelld is/oulld 
towards poorer survival/or patiellls with increased CD44v6 expressioll (lograllk tesl p=O.06) 
100 ~~-~ 
80 
:1 
co 60 normal cd44v6 n=12 
'" 'c;
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~ 40 
log rank p=O.06 
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8.4.4 CD44st and CD44v6 in lymph node metastases 
Twenty two lymph node metastases were investigated for CD44st and CD44v6 
expression. Increased CD44st expression was found in 45% (10/22) and CD44v6 
in 64% (14/22) of cases. In the lymph node metastases no significant correlation 
was found between CD44v6 and CD44st expression. Expression of CD44st in the 
lymph node metastases correlated significantly with CD44st expression in the 
primary adenocarcinoma; concordant staining was found in 85 % of cases 
(p<0.02). Increased CD44v6 expression in primary adenocarcinomas and lymph 
node metastases was concordant in 73% (16/22) of cases (p=O.I). In five cases 
CD44v6 was expressed in the primary adenocarcinoma but not in the lymph node 
metastasis, whereas in one case CD44v6 expression was seen in the lymph node 
metastasis but not in the corresponding adenocarcinoma. 
120 
8.5 Discussion 
Development of esophageal adenocarcinomas in Barrett's esophagus occurs 
through increasing dysplasia, concurrent with increased proliferation and 
accumulation of genetic abnormalities (1-9). Overall, patients with esophageal 
adenocarcinomas have poor prognosis. The presence of metastases is the most 
important factor predicting patient survival (14, 15). 
Expression of CD44st and certain CD44 splice variants have proven to be 
predictive for behavior of several malignancies. The CD44v6 splice variant 
expression has not only been associated with unfavorable clinicopathological 
characteristics in several carcinomas (20-24), but has also been observed in 
premalignant lesions such as in colon adenomas (29-31). 
In this study we present data on CD44st and CD44v6 expression in 35 cases of 
Barrett's esophagus with different degrees of dysplasia, in 70 esophageal 
adenocarcinomas associated with Barrett's esophagus, and also in 22 lymph node 
metastases. Although in control epithelia a consistently higher number of cells 
stained positive for CD44v6 than for CD44st, in these epithelia CD44st and 
CD44v6 staining was clearly correlated. 
In Barrett's esophagus we compared CD44st and CD44v6 expression with grade 
of dysplasia and proliferation rate. CD44st expression increased along with 
increased dysplasia and proliferative activity, but CD44v6 did not. In literature a 
similar correlation between CD44 and proliferation was noted for colonic 
epithelium and adenomas (33). Also in gastric intestinal metaplasia increased 
CD44 expression was observed (20). CD44v6 expression in Barrett's esophagus 
did neither correlate with dysplasia nor with proliferation nor with CD44st 
expression. Excessive CD44v6 expression was seen in all cases of Barrett's 
esophagus with high grade dysplasia but was also observed in many cases with 
low grade and some cases without dysplasia. This indicates that increased 
CD44v6 expression is an early event during neoplastic transformation in Barrett's 
esophagus. In contrast, in colon adenomas increased CD44v6 expression has 
almost exclusively been observed in areas with high grade dysplasia (29-31). 
In the esophageal adenocarcinomas, increased CD44st was observed in a lower 
number of cases than CD44v6 expression (50% versus 83 % respectively). 
Gunther! et al. (34), observed that not only epitopes of the variable portion of the 
CD44 molecule, but also the standard part of the CD44 molecule may be 
differentially expressed. As we used a monoclonal antibody which recognizes 
only one epitope of the CD44st domain, this may explain why a number of 
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carcinomas with increased CD44v6 immunostaining did not stain for CD44st. 
Alternatively, differences in epitope affinity of the anti CD44st and CD44v6 
antibodies, resulting in different staining intensities, may have confounded the 
staining results. 
The proportion of cases with increased CD44st and CD44v6 found in this study 
for esophageal adenocarcinomas is comparable to that found for other gastro-
intestinal carcinomas (20, 24). Interestingly, univariate analysis showed a trend 
of increased CD44v6 expression to be correlated with poorer survival (p=0.06). 
Also breast and colon carcinomas as well as in non-Hodgkin lymphomas CD44v6 
expression is significantly correlated with survival (35). 
Sixty four per cent (14122) of the lymph node metastases showed increased 
CD44v6 staining. Interestingly in 5116 cases CD44v6 expression was not 
increased in the lymph node metastases. Since most carcinomas showed 
heterogeneous CD44v6 expression, it is likely that metastatic competence is not 
limited to the CD44v6 positive cells. Alternatively, progression of metastasized 
carcinoma cells may lead to loss of CD44v6 expression. 
Expression of CD44v6 has been associated with increased malignant behavior, in 
spite of the fact that in many epithelia these variants are normally expressed (29, 
36). To differentiate between regulated and abnormal CD44v6 expression in 
Barrett's esophagus, investigation of the expression of splice variants expression 
at mRNA level would be necessary(20). Unfortunately, the parafrm embedded 
material used in this study did not allow these analyses. Moreover, for clinical 
practice RNA analyses-assays are too laborious, demanding special conditions for 
tissue preservation in order to obtain liable results. Assessment of progression 
specific expression of epitopes of the CD44 molecule which are specific tumor 
progression markers may be more applicable for clinical use. Recently, intron 9 
of CD44 has been found to be expressed in 80% of colon adenocarcinomas and 
to be expressed in several cell-lines of gastro intestinal origin (37). As expression 
of an intron sequence is an abnormal event and presumably the result of gene 
derangement, immunohistochemical assessment of these epitopes may be more 
tumor specific. However, expression of CD44st and CD44 splice variants is 
complicated and yet not fully understood. This caveat calls for careful 
interpretation immunohistochemical staining. 
In conclusion, we have found in Barrett's esophagus expression of CD44v6 splice 
variant early during development of neoplastic transformation, reaching a high 
incidence in esophageal adenocarcinomas. At present inununohistochemical 
staining of CD44 epitopes do not have diagnostic value for evaluation of 
122 
Barrett's esophagus and esophageal adenocarcinomas. 
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Chapter 9 
Concluding Remarks 

9.1 Model 
In this study several biological markers were investigated in premalignant 
Barrett's esophagus and esophageal adenocarcinoma. The aim was to detennine 
the prognostic value of these markers in premalignant and malignant stages. This 
was done by correlating several biological parameters in different stages of 
disease, ranging from non dysplastic intestinal type of metaplasia through low 
grade and high grade dysplasia to adenocarcinoma and lymph node metastases. 
Based on the presented results and the literature data, we propose a model with a 
step wise evolution, in which the significance of these markers during the process 
of malignant transformation is evaluated (Figure 1). In this chapter I will refer to 
the paragraphs in chapter 2 in which the original literature has been discussed. In 
the model, secretory factors, such as O-acetylated sialomucins and sucrase-
isomaltase (Chapter 2.2) and growth factors such as TGF-Alpha and EGF-R 
(Chapter 2.4) are frequently found in high levels in non dysplastic as well as in 
dysplastic intestinal type of Barrett's mucosa. Therefore, these factors do not 
seem to identify the group of Barrett's esophagus patients which has an 
Figure 1. Molecular evellts as they llIay occllr alollg the sequence oj metaplasia to [ow alld high grade 
dysplasia, alld subsequemly to adellocarcinoma alld metastasis 
Intestinal type metaplasia 
Q O~acetylated sialomucins, Sucrase~ 
isomaltase, EGF·R, TGF-alpha 
Low grade dysplasia 
Q Glutathione, P53, aneuploidy, V-Chromosome loss C·erbB2, APC, MCC 
High grade dysplasia 
Q H·Ras 
Adenocarcinoma 
Q E·Cadherin, Alpha· and Bela·Calenin, CD44-v6, C·erbB2 
Metastasis 
increased risk for developing an adenocarcinoma. 
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Parameters which do seem to be associated with neoplastic progression are 
decreased glutathione and glutathione-S transferase enzyme activity (Chapter 2.2) 
increased proliferative activity (Chapter 2.3), aneuploidy (Chapter 2.8) aberrant 
p53 (Chapter 2.6) and Y-chromosome loss (Chapter 2.7). Typically, these 
markers are observed at low frequency in non dysplastic Barrett's esophagus, 
they are increasingly observed along with increasing dysplasia and a high 
frequency is reached in high grade dysplasia and in the adenocarcinomas. In a 
prospective follow-up study the majority of Barrett's esophagus patients with 
aneuploidy or increased tetraploidy in their initial biopsy specimens progressed 
towards high grade dysplasia or carcinoma, whereas patients without these 
abnormalities did not (Chapter 2.8). In chapters 5, 6 and 8, the correlation of 
increased proliferation rate, p53 protein accumulation, aneuploidy and Y-
chromosome loss with dysplasia was studied. In chapter 5, we report increased 
levels of proliferation in intestinal type of metaplasia with and without dysplasia. 
However, detailed analysis of proliferation in Barrett's esophagus revealed that as 
the epithelium becomes dysplastic the zone of proliferating cells tends to expand 
to the luminal surface of the mucosa. A similar expression pattern was observed 
for CD44st (chapter 8). 
The evolution from low grade to high grade dysplasia is characterized by 
increasing genetic instability. Proliferation rate and aneuploidy increase (Chapter 
2.3, 2.8, 5, 8). In addition to p53 aberrations other tumor suppressor genes and 
oncogenes such as APC, and H-ras showed abnormalities (Chapter 2.5, 2.6). It 
is not known in which order these genetic aberrations occur and neither whether 
the order is at all of importance. Nevertheless, there is evidence that p53 (l7p) 
aberrations precede aneuploidy and APC (5q) gene loss (Chapter 2.7). 
For dysplastic cells to become invasive cancer cells a crucial step is the moment 
they acquire the ability to break through the basement membrane and invade 
surrounding tissues. In frankly invasive adenocarcinomas the accumulation of 
numerous genetic aberrations have been seen (Chapter 2). However, little data is 
available about genetic events specifically involved in transition from high grade 
dysplasia into adenocarcinoma. In a small series H-ras expression was observed 
in high grade dysplasia and adenocarcinomas but not in low grade dysplasia, nor 
in non dysplastic epithelium (Chapter 2.5). This suggests an important role of 
H-ras in the transition from high grade dysplasia to adenocarcinoma. 
Perhaps the most fascinating step in carcinogenesis is the formation of 
metastases. Formation of metastases is a complex process in which many factors 
are involved. In this process, epithelial cells are liberated from their original 
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compartment, break through the basement membrane, invade lymph and blood 
vessels, adhere to a new environment and proliferate. It has been observed that 
esophageal adenocarcinomas with limited invasion of the esophageal wall already 
may have metastasized (Chapter 1.3). It seems that as soon as cells invade the 
submucosa, metastatic ability is rapidly acquired. In a few studies aneuploidy was 
found to correlate with the presence of metastases and poor survival (Chapter 
2.8). Another study showed a correlation between C-erbB2 expression and poor 
survival (Chapter 2.5). Recently, cell surface molecules and their role in tumor 
cell behavior gained interest. Cell surface molecules, such as those involved in 
the E-Cadherin-Catenin complex and CD44 with its splice variants, play an 
important role in tumor invasiveness and metastatic ability (Chapter 2.9, 2. to). A 
high frequency of decreased expression of E-Cadherin was found in esophageal 
adenocarcinomas (Chapter 2.9). In our studies decreased expression of Alpha-
and Beta-Catenin was found to occur roughly in the same frequency as E-
Cadherin expression (Chapter 7). Interestingly, in a subset of carcinomas without 
metastases and sometimes with limited invasion of the esophageal wall, decreased 
expression of these proteins correlated with poor survival (Chapter 7). Another 
interesting cell surface molecule studied in this thesis is CD44. It has become 
apparent that the expression of the CD44v6 splice variant is associated with 
increased tumor invasiveness and metastatic ability (Chapter 2. to). We detected 
increased CD44v6 splice variant expression in a high percentage of esophageal 
adenocarcinomas (Chapter 8). A trend was found between increased CD44v6 
expression and poor five year survival. Surprisingly, a high level of CD44v6 
expression was found in Barrett's esophagus as well (Chapter 8). 
9.2 In conclusion 
In conclusion, in the progression of Barrett's esophagus via dysplasia to 
carcinoma and the development of metastases formation numerous parameters are 
involved. In this study p53 protein accumulation, aneuploidy, Y-chromosome 
loss, high expression of the CD44st molecule and increased proliferation rate 
were found to go along with increasing dysplasia. These markers may identify 
Barrett's esophagus at risk for neoplastic progression. Nevertheless, if these 
markers were to be applied for clinical decision making, their relevance should 
be evaluated in long term follow up studies of patients with Barrett's esophagus. 
For most of these parameters long tenn follow up studies are lacking. 
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The most promising marker investigated is p53. During neoplastic progression 
mutation of the p53 gene seems to be a key event which is followed by several 
other genetic alterations. In addition to histological grading of dysplasia, 
detection of p53 aberrations might become an important diagnostic tool. 
A remarkable observation in this study was loss of the Y -chromosome, which 
occurs as dysplasia increases. The meaning of Y -chromosome loss is unclear. At 
present no specific genes involved in tumorigenesis have been located on the Y-
chromosome. Therefore, Y-loss is considered a random effect, reflecting genetic 
instability and as such is a parameter to detect neoplastic progression in male 
Barrett's esophagus patients. 
The transformation of high grade dysplasia into adenocarcinoma is poorly 
understood. Possibly the same factors involved in tumor invasiveness and 
metastatic behavior of esophageal adenocarcinomas are involved in this 
transitional step. Future investigation of biological markers involved in tumor 
behavior in high grade dysplasia and early carcinomas are of major importance. 
With respect to tumor behavior and metastasis decreased expression of the cell 
surface molecules E-Cadherin, Alpha- and Beta-Catenin and increased expression 
of CD44v6 in esophageal adenocarcinomas were found to correlate with poor 
survival. Although these results may seem useful for clinical applications, the 
underlying mechanisms involved in up and down regulation of these factors are 
poorly understood and should be explored in more detail. For instance, there is a 
complicated interaction between the E-Cadherin-Catenin complex and several 
intracellular factors such as the tumor suppressor APC and the C-erbB2 
oncogene. Concerning CD44 splice variants, little is known about their 
interactions and regulation of expression. Therefore, the use of the expression of 
cell surface molecules for predicting survival at this moment is premature. 
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Summary 
Barrett's esophagus is a condition in which, due to chronic gastro-esophageal 
reflux, the normal squamous epithelium is transformed into columnar epithelium. 
Compared to the general population, patients with Barrett's esophagus have an 
increased risk of 30 to 120 fold for developing esophageal adenocarcinomas. 
Malignant transformation of Barrett's esophagus is a gradual process which is 
reflected in histological changes, classified as low and high grade dysplasia. 
Unfortunately, most patients with Barrett's esophagus have no or few symptoms 
(gastro-esophageal reflux), and esophageal adenocarcinoma is often detected in 
advanced stage of disease. During the past decades there has been an alarming 
rise in the incidence of esophageal adenocarcinomas. In Western countries the 
incidence of esophageal adenocarcinomas reaches almost 1 per 100.000 per year. 
The prevalence is highest in white middle aged males of higher socio-economic 
classes. Esophageal adenocarcinomas are frequently metastasizing tumors 
associated with an average five year survival of less than 20%. However, in case 
treated in an early stage of the disease, survival improves significantly. 
In this thesis studies concerning neoplastic progression of Barrett's esophagus and 
metastases formation in esophageal adenocarcinomas are reported. In our studies 
we analyzed several biological parameters in non dysplastic and dysplastic 
Barrett's esophagus, in esophageal adenocarcinomas and metastases. In a pilot 
study aneuploidy, p53 protein accumulation and numerical chromosomal 
aberrations such as chromosome 17- and Y-loss in adenocarcinoma and Barrett's 
esophagus were detected. P53 protein accumulation was evaluated in over a 
hundred biopsy specimens of patients with Barrett's esophagus with varying 
degrees of dysplasia and in 24 esophageal adenocarcinomas. In approximately 
80% of the adenocarcinomas p53 protein had accumulated. In Barrett's 
esophagus a significant correlation was found between p53 protein accumulation 
and increasing dysplasia. In a subsequent study aneuploidy and the status of X 
and Y -chromosome was investigated in a series of 50 biopsy specimens of 
patients with Barrett's esophagus and in 23 adenocarcinomas. Aneuploidy and Y-
chromosome loss were found to correlate with dysplasia. The frequencies of both 
parameters reached 70-100% in high grade dysplasia and adenocarcinomas. Other 
parameters investigated in Barrett's esophagus have been the expression of the 
cell surface molecules CD44st and CD44v6 splice variant and proliferation rate. 
Expression of these parameters has been investigated in different compartments 
of the Barrett's esophagus mucosa. As dysplasia increased proliferation and 
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CD44st expression were seen more often at the luminal side of the crypts. 
CD44v6 splice variant expression, a cell surface molecule associated with 
aggressive tumor behavior, was highly expressed in both non dysplastic and 
dysplastic epitilelium. The metastatic behavior of esophageal adenocarcinoma has 
been studied by evaluation of cell surface markers with respect to 
clinicopathological parameters. These markers are associated with increased 
invasiveness and metastatic ability of carcinomas. Decreased expression of the 
adhesion molecules, E-Cadherin, Alpha- and Beta-Catenin were found in 60 to 
70% of carcinomas. Decreased expression of all three proteins correlated with 
poor differentiation grades. Independent of stage, E-Cadherin and Beta-Catenin 
correlated with poor survival. Increased expression of the cell surface molecules 
CD44st and its CD44v6 splice variant was found in 50 and 83% respectively. 
There was a trend between CD44v6 expression and five year survival. 
In this thesis global knowledge has been acquired concerning carcinogenesis, 
tumor behavior and metastases formation. However, many questions remain to be 
answered concerning the complex biological mechanisIll5 which are involved in 
expression of the various parameters. On the other hand, long term follow up 
studies of Barrett's esophagus patients are necessary to proof the clinical value of 
the several parameters. As knowledge of the biological mechanisIll5 involved in 
carcinogenesis increases, this knowledge will be increasingly applied for choosing 
the best treatment modality for the individual patient. 
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Samenvatting 
Barrett oesofagus is een aandoening, waarbij het normale niet verhoomend 
meerlagig plaveisel epitheel van de oesofagus, door langdurige gastro-oesofageale 
reflux, is veranderd in cilindrisch epithee!. Patienten met een Barrett oesofagus 
hebben vergeleken met de normale bevolking een 30 tot 120 maal verhoogd 
risico voor het krijgen van een oesofagus adenocarcinoom. Maligne transformatie 
van Barrett epitheel is een geleidelijk proces, dat wordt gekenmerkt door 
histologische veranderingen. Binnen deze histologische veranderingen wordt 
onderscheid gemaakt tussen niet dysplastisch, licht en sterk dysplastisch epithee!. 
Het merendeel van de patienten met een Barrett oesofagus heeft geen (reflux) 
klachten, waardoor veel oesofagus adenocarcinomen in een laat stadium worden 
ontdekt. Gedurende de afgelopen decennia is de incidentie van oesofagus 
adenoarcinomen a1armerend toegenomen. In Westerse landen is deze incidentie 
bijna 1 per 100.000. De belangrijkste risico groep voor het krijgen van een 
oesofagus adenocarcinoom wordt gevormd door blanke mannen van middelbare 
leeftijd uit een hoog socio-economische milieu. Oesofagus carcinomen zijn 
geassocieerd met vroege metastasering en een vijf jaars overleving van minder 
dan 20 %. De overleving verbetert significant indien de ziekte in een vroeg 
stadium wordt ontdekt. 
In dit proefschrift is de maligne progressie van Barrett oesofagus en het 
progressieve gedrag van oesofagus adenocarcinomen onderzocht. Verschillende 
biologische factoren werden bestudeerd in niet dysplastisch en dysplastisch 
Barrett epitheel, in oesofagus adenocarcinomen en in lymfklier metastasen. In een 
'pilot' studie werden aneuploidie, p53 proteine accumulatie en numerieke 
chromosomale afwijkingen, zoals verlies van chromosomen 17 en Y ontdekt. 
Deze bevindingen werden in de daarop volgende studies verder geevalueerd. 
Aberrante accumulatie van het p53 eiwit werd in meer dan 100 biopten met 
verschillende graden van dysplasie en in 24 oesofagus adenocarcinomen bekeken. 
Accumulatie van p53 werd in ongeveer 80% van de adenocarcinomen gezien. In 
Barrett oesofagus correleerde p53 accumulatie significant met toenemende 
dysplasie. In de studie die hierop volgde werden aneuploidie en de status van het 
X en Y -chromosoom bestudeerd in 50 biopten van patienten met Barrett 
oesofagus en in 23 oesofagus adenocarcinomen. Zowel aneuploidie en verlies van 
het Y chromosoom correleerden significant met toenemende dysplasie. Beide 
parameters hadden een frequentie van 70-100% in biopten met sterke dysplasie 
en in de adenocarcinomen. Andere parameters die in Barrett oesofagus werden 
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onderzocht zijn proliferatie, CD44st en CD44v6 expressie. Expressie van deze 
factoren werden in verschillende compartimenten van de villi in het Barrett 
epitheel gescoord. Naarrnate de dysplasie toeneemt werden expressie van CD44st 
en proliferatie van het epitheel vaker in het luminale compartiment van de villi 
gezien. 
Het metastaserend gedrag van de oesofagus adenocarcinomen werden onderzocht 
door evaluatie van de cel membraan markers, E-Cadherine, Alpha-, Beta-
Catenine, CD44st en CD44v6. Expressie van deze molekulen werd met 
betrekking tot clinico-pathologische parameters geevalueerd. Aberrante expressie 
van deze moleculen zijn geassocieerd met toegenomen invasiviteit en metastase 
capaciteit van tumoren. Verlaagde expressie van de adhesie moleculen E-
Cadherine, Alpha- en Beta-Catenine werd in 60-70% van de adenocarcinomen 
waargenomen. Deze verlaagde expressie correleerde met een slechte differentiatie 
graad van de adenocarcinomen. Verlaagde expressie van E-Cadherine en Beta-
Catenine correleerden significant met een slechtere vijf jaars overleving. 
Toegenomen expressie van CD44st en CD44v6 werden in respectievelijk 50 en 
83 % van de tumoren gezien. Een trend werd gevonden tussen verhoogde 
expressie van CD44v6 en vijfjaars overleving. 
Ten slotte wordt in dit proefschrift een model voorgesteld waarin de 
prognostische waarde van verschillende markers worden geevalueerd. 
Proliferatie, aneuploidy, p53 en Y-chromosoom verlies zijn potentieel factoren 
die in een vroege fase patienten met Barrett oesofagus kunnen identificeren met 
een verhoogde risico op het ontwikkelen van een oesofagus adenocarcinoom. In 
oesofagus adenocarcinomen zijn met name E-Cadherine en Beta-Catenine de 
veelbelovende prognostische factoren. 
In dit proefschrift werd algemene kennis opgedaan over tumorigenese en tumor 
gedrag. Er zijn echter nog veel onbeantwoorde vragen met betrekking tot de 
complexe biologische mechauismen die ten grondslag liggen aan de verschillende 
observaties. Het uitvoeren van follow-up studies van patienten met Barrett 
oesofagus zijn essentieel om de klinische relevantie van de verschillende 
onderzochte factoren in Barrett oesofagus aan te tonen. De verwachting is dat, 
naarmate kennis betreffende tumorigenese en tumor gedrag toeneemt, het gebruik 
van biologische parameters am de beste behandeling voor de individuele patient 
te kunnen kiezen steeds belangrijker zal worden. 
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List of abbrevations 
AC: Alpha-Catenin 
APC: Adeno-polyposis coli gene 
BC: Beta-Catenin 
CD44st: Standard part of CD44 molecule 
CD44v6: V6 splice variant of CD44 molecule 
DAB: Diaminobenzidine tetrachloride 
DCC: Deleted in colon carcinoma gene 
DO-7: Monoclonal antibody against p53 
EC: E-Cadherin 
EGF: Epidermal growth factor 
EGF-R: Epidermal growth factor receptor 
FCM: Flow cytometry 
IRC: Immunohistochemistry 
ISH: In situ hybridization 
kDa: kilodalton 
LOH: Loss of heterogeneity 
MCC: Mutated colon carcinoma gene 
Mib-I: Monoclonal antibody against Ki-67 antigen 
ODC: Ornithine decarboxylase 
P53: Protein of 53 kDa 
PBS: Phosphate buffered saline 
PCNA: Proliferating cell nuclear antigen 
PCR: Polymerase chain reaction 
PI: Proliferation index 
17p: Short arm of chromosome 17 
15q: Long arm of chromosome 15 
Rb: Retinoblastoma gene 
RFLP: Restriction fragment length polymorphism 
SSCP: Single strand conformation polymorphism 
TGF-Alpha: Transforming growth factor -alpha 
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